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Mature muscle is susceptible to chronic stress and disease leading to muscle wasting known as 
atrophy. A severe loss in skeletal muscle mass and function directly contributes to disease 
progression and early death as seen in multiple myopathies, cancer, neurodegenerative and 
cardiovascular diseases, and from catabolic conditions including ageing, fasting and limb 
immobilisation. Muscle mass is maintained by protein turnover rates and fibre type 
composition, which is in part under the control of key genes and their protein products. In 
recent times, small non-coding genes called microRNAs (miRNAs), have also been identified 
to play important modulatory roles in controlling protein levels during stress and disease in 
muscle. While the molecular mechanisms that regulate muscle atrophy are well studied, our 
understanding remains incomplete. Hence, there is a need to delineate further the molecules 
that control muscle mass in order to develop effective therapeutic strategies to combat 
degenerative muscle conditions. 
N-myc downstream-regulated gene 2 (Ndrg2) is a stress responsive gene that is highly 
expressed in skeletal muscle. Expression of NDRG2 is typically induced under catabolic 
conditions in skeletal muscle and in other tissues. Previously, in vitro studies have also shown 
that NDRG2 promotes myoblast proliferation and protects against hydrogen peroxide-induced 
oxidative and endoplasmic reticulum (ER) stress. Interestingly, NDRG2 overexpression 
reduces protein synthesis in mouse myotubes under basal but not catabolic conditions. Together, 
these findings suggest that increased levels of NDRG2 during catabolic stress may be adaptive 
to help maintain muscle mass. While the expression of NDRG2 in muscle tissues is confirmed, 
the molecular factors that regulate NDRG2 in skeletal muscle and the role NDRG2 plays during 
catabolic conditions is largely unknown. Therefore, this thesis aimed to investigate miRNA 
regulation of NDRG2 in skeletal muscle cells and to characterise the effect of NDRG2 
overexpression in skeletal muscle under catabolic stress conditions in vivo.    
In the first study presented in this thesis, three miRNAs, mmu-miR-23a-3p (miR-23a), mmu-
miR-23b-3p (miR-23b) and mmu-miR-28-5p (miR-28), were identified using an in silico 
approach. Their ability to bind and inhibit the 3’ untranslated region of the mouse Ndrg2 gene 
was confirmed through luciferase reporter assays. However, neither miR-23a, -23b nor -28 
overexpression had any influence on endogenous Ndrg2 mRNA or protein levels up to 48 h 
2 
 
post treatment in mouse C2C12 myotubes. Interestingly, a compensatory decrease in the 
miRNA endogenous levels in response to the overexpression of the other miRNAs was 
observed at various time-points. A cocktail of all three miRNAs was then combined to 
determine if together they could suppress endogenous NDRG2 expression. Under basal 
conditions, no change in NDRG2 mRNA or protein expression was evident; however, when 
dexamethasone treatment, a catabolic stress, was applied, the miRNA cocktail suppressed the 
induction of NDRG2 expression by dexamethasone up to 25%. In conclusion, these findings 
identify a potential modulatory role for miRNAs in regulating NDRG2 expression during 
catabolic stress conditions in muscle cells. 
Most of the muscle growth in early life occurs through postnatal myogenesis. NDRG2 controls 
myoblast proliferation and differentiation. Hence, the aim of this study was to overexpress 
NDRG2 in neonatal myofibres and progenitor cells to determine effects on postnatal 
myogenesis. The primary aim was to determine suitable viral vectors to overexpress NDRG2 
specifically in neonatal skeletal muscle. Therefore, custom-designed adeno-associated virus 
serotype (AAV1) and lentiviral (LTV) viruses containing the muscle specific promoters, α-
actin and desmin, respectively, were used to determine their ability to overexpress NDRG2 in 
neonatal muscle fibres and progenitor cells. Four weeks post systemic injection of the highest 
LTV dose into 3 day old neonates did not cause NDRG2 overexpression. Further testing in 
vitro and in vivo demonstrated that the viruses driven by muscle specific promoters did not 
increase exogenous NDRG2 levels in cultured myoblasts and myotubes or in the tibialis 
anterior (TA) muscle when injected intramuscularly. However, an AAV1 construct designed 
to overexpress human NDRG2 using a CMV promoter successfully expressed human NDRG2 
in mouse TA muscle. These findings indicate that the muscle-specific AAV and LTV viruses 
designed to overexpress NDRG2 specifically in muscle cells were unable to do so efficiently. 
Therefore, the hypothesis that NDRG2 could promote or alter postnatal growth through 
hyperplasia or hypertrophy could not be tested. 
Understanding how skeletal muscle mass is controlled during different stress conditions in vivo 
is fundamental to our knowledge of understanding how a mammalian organism maintains 
healthy muscle. The aim of this study was to determine whether increased levels of NDRG2 
altered skeletal muscle mass or stress response pathways in skeletal muscle under fasting 
conditions. Mouse NDRG2 was overexpressed using AAV in the right TA muscle and a control 
AAV was injected into the left TA muscle. Four and eight weeks post injection, mice were 
fasted for 24 hours or remained fed prior to the harvesting and analysis of the TA muscles. 
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Body weights and glucose levels were reduced significantly in fasted mice. Muscle tissues were 
analysed for expression changes in proteins representing protein degradation, autophagy and 
muscle fibre type. Fasting induced the expression of the E3 ligase ubiquitin genes MuRF1 and 
atrogin-1, increased levels of the autophagy protein LC3, and increased endogenous NDRG2 
levels. While reduced TA muscle weights were recorded following NDRG2 overexpression, 
no change was observed in the type and cross-sectional area of the muscle fibres, on the 
expression of E3 ligases or autophagy marker proteins, or on the MAPK stress signalling 
pathways in fed or fasted state indicating that increased expression of NDRG2 is unlikely to 
play a significant role in the muscle’s adaptive response to fasting. 
ALS is a neurodegenerative disease characterized by the death of motor neurons leading to 
severe muscle wasting, paralysis and death within 2-3 years of diagnosis. Key pathological 
features of ALS in skeletal muscle include oxidative and ER stress, and apoptosis. As NDRG2 
has shown protective effects against H2O2-induced stress in vitro, we sought to extend these 
studies and to investigate whether increased levels of NDRG2 could alleviate oxidative and ER 
stress in a mouse model of ALS, the superoxide dismutase 1 (SOD1)G93A transgenic mouse. A 
proof-of-concept study was undertaken in SOD1G93A transgenic and littermate control wildtype 
(WT) mice following the intramuscular administration of AAVs overexpressing mouse 
NDRG2 or a control virus into contralateral TA muscles when the SOD1G93A mice are early 
symptomatic. Overexpression of NDRG2 was achieved in TA tissues and endogenous NDRG2 
protein expression levels were significantly higher in the TA muscle of ALS models when 
compared to WT mice. Reactive oxygen species (ROS) and ER stress-response proteins 
including BiP/GRP78, CHOP and caspase 3 were significantly increased in the SOD1G93A mice 
compared to WT mice; however, no difference in ROS levels, ER stress markers or 
mitochondrial content as reflected by citrate synthase activity was found between the AAV 
control and NDRG2 treated muscles. 
Findings from this thesis evaluate the mechanism of regulation of NDRG2 in muscle cells and 
extend previous in vitro findings to investigate its role and function in vivo in different muscle 
wasting conditions. The findings demonstrate that multiple miRNAs are likely required to 
suppress NDRG2 protein translation in muscle myotubes under catabolic stress conditions. 
Moreover, NDRG2 was increased in SOD1 and fasted muscles compared to healthy control 
mice. Future investigation into miRNA regulation of NDRG2 in vivo under diseased conditions 
might unveil an avenue to treat muscle loss under stressed conditions. Moreover, knocking 
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down NDRG2 in muscle atrophying conditions could further delineate whether it plays a role 


































CHAPTER 1 - Literature Review 
 
1. 0. Introduction to Skeletal Muscle       
Skeletal muscle represents approximately 40% of the total body mass. It co-ordinates 
movement through its attachment to the skeleton and is highly innervated and vascularized. 
Therefore, skeletal muscle is a heterogeneous, complex and metabolically active tissue 
involved in a range of vital functions including maintenance of thermal homeostasis, body 
posture and energy metabolism (1, 2). Moreover, it has the ability to regenerate after damage 
due to general use, acute stress, disease and injury, and to adapt to increased energy demands 
following exercise training by regulating muscle fibre size, mass and metabolism (3, 4). 
However, during extreme stress conditions, the loss of skeletal muscle mass and function 
directly contributes to disease progression, severity and early death, as seen in multiple 
myopathies and neuromuscular diseases, or indirectly, as seen in chronic diseases including 
cancer, musculoskeletal and cardiovascular diseases. Importantly, a larger muscle mass is 
associated with enhanced recovery from chronic illness (5-7), and maintaining skeletal muscle 
throughout life delays age-related muscle wasting, referred to as sarcopenia. The muscle 
wasting and associated weakness in our ageing population contribute significantly to the loss 
of independence and fall-related deaths in the elderly (8-10). Fall-related acute care for the 
elderly in Australia was estimated at $566 million in 2003-04 (11) and rose up to more than 
$648 million in 2008-09 (12). The cost increased further even though the rate of hip fractures 
decreased by 2% per year while head injuries increased at high rates of 7% per year due to falls 
from 2002-03 and 2012-13 (13). It is anticipated that the total health costs attributed to injurious 
falls may dramatically increase several fold by 2051 (14).  Hence, understanding the molecular 
mechanisms regulating muscle mass and identifying new strategies to maintain skeletal muscle 
mass and function is important to combat muscle wasting associated with injuries, disease and 





1. 1. Muscle Mass Maintenance  
Skeletal muscle is one of the most dynamic and plastic tissues in the human body. After birth, 
muscle continues to develop through the process of postnatal myogenesis, which includes both 
new muscle cell growth (hyperplasia) and the expansion of pre-existing muscle fibres through 
increased protein synthesis (hypertrophy). Skeletal muscle constitutes 25% of human and 
rodent body weight at birth (15) which grows to approximately 40% during the postnatal period 
irrespective of their size (15, 16). Most of the postnatal growth occurs in the first three weeks 
in mice (17) and until approximately 18 years of age in humans (16). Mouse models are used 
to study diseases and biological processes as they have many similarities to humans in terms 
of anatomy, physiology and genetics. In adults, muscle mass generally increases further under 
hypertrophic (anabolic) conditions such as in response to endurance training, and can undergo 
new muscle growth to repair and replace muscle lost from injury through the activation of 
muscle satellite cells. Conversely, muscle mass decreases (atrophy) in response to disease and 
degenerative (catabolic) conditions when protein degradation rates outweigh protein synthesis. 
In combination, muscle mass is regulated by a balance between protein synthesis and 
degradation, postnatal myogenesis and muscle repair, and changes to muscle fibre type 
composition in response to anabolic or catabolic stressors. Together, these processes are 
regulated by multiple key genes and the proteins they encode, many of which are modulated 
by small, non-coding genes known as microRNAs (miRNAs), to help maintain muscle mass 
and function. An overview of these processes including specific conditions and diseases, the 
signalling pathways and the role of key miRNAs and genes in the control of muscle mass will 
be reviewed below. 
        
   
1. 2. Muscle Mass Increases during Postnatal Myogenesis 
Skeletal muscle is a multinucleate syncytium. It is generated from the fusion of mononuclear 
myoblasts that mature into multinucleated myofibres through the process of myogenesis (18, 
19). Skeletal muscle development begins during embryogenesis and ends only after postnatal 
growth during which an organism attains its fully developed size.  During embryonic 
myogenesis, muscle fibre development occurs through two distinct cell populations. Initially, 
muscle fibres of the body are generated from foetal myoblasts, which, form a template and give 
rise to additional fibres. Secondly, myoblasts arising from embryonic somitic progenitors do 
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not form myofibres. They instead stay close to the basal membrane of existing fibres in a 
quiescent state and are known as muscle satellite cells.  These cells express both paired-box 
transcription factor proteins, Pax3 and Pax7, and occupy this particular location towards the 
end of embryonic muscle development. Pax7 is essential for the specification of these cells 
during muscle development (20); however, later studies have shown that Pax3, a close relative 
to Pax7, also plays a critical role in postnatal muscle growth and following injury and repair 
(21, 22). These Pax3/Pax7 positive cells proliferate and serve as a source of new myonuclei 
during postnatal growth and development (23, 24). A number of myogenic regulatory factors 
(MRFs) involved in the different steps of postnatal myogenesis are shown in Figure 1.1.  In 
mice, body weight increases 7-8 fold during the first three weeks of postnatal life, most of 
which is accounted for by the increase in skeletal muscle mass only (15). Postnatal muscle 
growth occurs mainly through hypertrophy of myofibres in mice rather than a rise in fibre 
number (hyperplasia) (17). Primarily, this hypertrophic growth is attributed through both 
protein deposition and the differentiation of myogenic stem cells synthesizing new myotubes. 
During muscle growth, however, a dramatic size-independent increase in mechanical abilities 
occurs as well. Progenitor cells are satellite cells determined for myogenic fate and reside on 
muscle fibres. Muscle satellite cells comprise one-third of quiescent nuclei in mouse during the 
first week of postnatal growth (25-27). Most of these satellite cells (~80%), now known as 
myoblasts, are proliferating (28, 29), however, just after three weeks of postnatal phase, the 
percentage of proliferating cells declines sharply (30). Finally, a greater number of satellite 
cells enter quiescence in the mature muscle (31) with only less than 1% demonstrating cell 
division in 6 to 8-week-old mice (32). Furthermore, the percentage of satellite cells decreases 
gradually as muscle develops (17, 25, 33). Normal muscle development during the early 
postnatal life is critical and any defect in it can permanently alter later skeletal muscle growth, 
contractile function and metabolic maturation (34-38). Therefore, postnatal growth and 






Figure 1. 1. Postnatal muscle development invokes skeletal muscle progenitor cells within 
the satellite cell pool that proliferate, terminally differentiate and fuse to generate 
multinucleated myotubes under the control of MRFs including MyoD, Myf5 and myogenin. 
Satellite cells are Pax7 and Pax3 positive (36). 
 
 
1. 3. Protein Turnover 
Single muscle fibres, apart from their water content, are made mostly of contractile, regulatory 
and cytoskeletal proteins (39). With the advent of modern proteomics, understanding the 
protein components of skeletal muscle fibres has substantially advanced. Generally, muscle 
development, mass and maintenance depend on the balance between muscle protein synthesis 
and degradation rates. In addition, both of these processes are sensitive to a number of factors 
such as nutritional status, hormonal balance, physical activity, and injury/disease (40). Muscle 
hypertrophy results in increased muscle mass that follows whenever protein synthesis rates 
exceed that of protein degradation (41-43).  Within a muscle fibre, each nucleus regulates and 
controls the type of protein synthesized in the specific region of the cell (44). Protein expression 
of a single fibre within these regions is coordinated so that the type of protein expressed is 
similar through the length of the fibre (45). Resistance training in muscle is a potent stimulator 
of protein synthesis rates (46, 47).  In contrast, a decrease in muscle mass or atrophy occurs 
whenever protein degradation rates exceed that of protein synthesis (41, 48).  Skeletal muscle 
atrophy is a devastating consequence of several chronic diseases including cancer, diabetes, 
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sepsis, chronic heart failure, rheumatoid arthritis, acquired immunodeficiency syndrome, 
Duchenne muscular dystrophy and amyotrophic lateral sclerosis (49). In addition, muscle 
atrophy is a well-known component of age-related muscle wasting, sarcopenia (50). The 
fundamental molecular mechanisms influencing protein synthesis and degradation rates and 
therefore causing muscle hypertrophy and atrophy are not well understood. Understanding 
these mechanisms is of global interest and will enhance further knowledge regarding muscle 
regeneration and maintenance.  
 
 
1. 4. Muscle fibre types  
Muscle fibres are the functional units of muscle. These fibres have the characteristic 
organization of the contractile and regulatory proteins into striated myofibrils resulting from 
repeating units known as sarcomeres. The sarcomere, in vertebrates, is a complex structure 
containing 28 different proteins and the pattern of these tend to repeat with a periodicity of 
nearly 2 to 3 μm (51). Approximately 70–80 % of the total protein content of a single muscle 
fibre is comprised of actin and myosin only (52). Myosins are hexamers, composed of two 
myosin heavy chains (MHCs) and four myosin light chains (MLCs), with each MHC 
associating with two MLCs (53). Myosin and its different isoforms determine the muscle fibre 
type (52).  Mammalian skeletal muscle MHCs have eight distinct isoforms or types: 1, 2A, 2X 
and 2B in adults; and embryonic, neonatal, α, and extraocular myosins are predominant during 
foetal development (54-56). Type 1 is expressed in slow twitch fibres and 2A, 2X and 2B are 
expressed in fast-twitch fibres. Type 1, 2X and 2A are present in all mammals, while 2B is 
expressed only in small mammals such as rodents and is absent in humans (57-60). The 
molecular pathways regulating muscle fibre size are complex and an overview depicting their 
interactions is shown in Figure 1.2. Differential sensitivity is demonstrated by fibre subtypes 
to specific atrophic signals. For instance, glycolytic type 2B and 2X fibres are more prone to 
prolonged fasting-induced atrophy while oxidative type 1 and 2A fibres are more resistant (61-
63). Conversely, type 1 fibres are typically affected by inactivity- and denervation-induced 





Figure 1. 2.  A schematic overview of different stresses and protein molecules modulating 




1. 5. Pathways and molecules regulating muscle mass 
 
1. 5. 2. Stress signalling pathways 
Muscle, being the largest pool of proteins in the body, serves as an amino acid source for energy 
purposes during catabolic conditions including fasting. Excessive muscle mass loss is 
associated with prognosis of myopathies and muscle dystrophies, as well as in cancer, diabetes, 
sepsis and heart failure. Muscle atrophy is an intricate process that ensues as a consequence of 
multiple stressors, including neural inactivity, mechanical unloading, inflammation, metabolic 
stress, and increased glucocorticoids (reviewed in (67)). The molecular and cellular pathways 
that regulate muscle atrophy are still being discovered, however, a number of key transcription 
factors, signalling pathways, and cellular processes involved in the initiation and sustained 
breakdown of muscle mass under a variety of conditions have been unravelled recently. Protein 
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turnover is regulated by a few important proteolytic systems, the ubiquitin-proteasome, the 
autophagy-lysosome and Ca2+ dependent proteases, calpain pathways (68).  
 
1. 5. 3. The ubiquitin-proteasome system 
Muscle mass decrease is linked to elevated ubiquitination levels of muscle proteins, increased 
ATP-dependent activity of proteasomes, increased breakdown of proteins and decreased the 
synthesis of new proteins, and upregulation of ubiquitin enzymes (E2) and ubiquitin protein 
ligases (E3) (reviewed in (69)). An overview of the process is shown in Figure 1.3. Multiple 
gene expression profiling experiments performed independently revealed that muscle atrophy 
is an active process with the upregulation of two genes coding for muscle specific E3 ubiquitin 
ligases, atrogin-1 and MuRF1 (70, 71). Knocking down of atrogin-1 prevents fasting induced 
muscle mass loss (72) where as MuRF1 knockout mice are resistant to muscle atrophy induced 
by dexamethasone (73) indicating both molecules as key regulators of muscle mass under 
catabolic stress. Another E3 ligase that is activated in muscle atrophy includes Trim32. Trim32 
catalyses the degradation of actin, tropomyosin, troponins, α-actinin and desmin (74) and 
knocking out Trim32 in mice shows compromised recovery from muscle loss and does not 
protect from muscle atrophy (75) suggesting that this protein may not be necessary for atrophy. 
 
Figure 1. 3. This figure demonstrates how different enzymes coordinate and carry out 




1. 5. 4. The autophagy-lysosome system 
Autophagy plays a critical role in cell turnover in both normal conditions and in response to 
stress stimuli including cellular stress, nutrient deprivation and amino acid starvation (76). 
Stimulation of autophagy in skeletal muscles ensues with the clearance of damaged cell 
components and dysfunctional mitochondria, which is imperative for muscle homeostasis (77). 
In mammals, delivery of autophagosome to lysosome occurs mainly through three mechanisms, 
macroautophagy, chaperone-mediated autophagy and microautophagy. During fasting, skeletal 
muscle has the highest rates of autophagosome formation and fast glycolytic muscles exhibit a 
higher content of autophagosomes than slow oxidative muscles (78). Multiple experiments and 
disease models helped in understanding the role of autophagy in muscle atrophy. For example, 
FoxO3 induced myofibre atrophy is partly prevented by knockdown of microtubule-associated 
protein 1A/1B-light chain 3 (LC3), the protein that contributes to autophagosome formation 
(79). This increased autophagy is attenuated by knockdown of LC3 that also causes 
preservation of muscle mass (80). In rodent muscles, 9.5 to 72 hours fasting increases lipidation 
of LC3-I to LC3-II (78, 81-83). This ratio of LC3-II/LC3-I through lipidation is generally 
considered an autophagy marker in multiple tissues including skeletal muscle. Generally, 
autophagy is a non-selective pathway of organelle degradation, however, it can elicit selective 
removal of particular organelles as well, as in case of mitochondria, referred to as mitophagy. 
The autophagy-lysosome system in skeletal muscles is essential as alterations to this process 
can lead to the pathogenesis of numerous genetic muscle diseases. In muscle homeostasis, 
autophagy plays a dual role of being detrimental as it contributes to muscle degeneration and 
can serve as a compensatory mechanism for muscle cell survival (84).  
 
1. 6. Muscle Stressors  
Skeletal muscle is highly responsive to different kind of stressors. These stresses, including 
mechanical and metabolic demands, elicit noticeable modifications in gene expression leading 
to hypertrophy or atrophy (85). Hypertrophy and atrophy stimulating factors impact skeletal 
muscle development and mass by regulating the muscle protein pool (86). They may be 
endogenous, which include changes in hormonal secretion, altered metabolism and neuronal 
innervation, or exogenous including disuse, injury, sedentary behaviour, decreased physical 
activity and nutrition effects. Growth promoting stressors such as growth hormones, anabolic 
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steroids, physical exercise and nutritional supplements bring about an increase in protein 
synthesis rates causing hypertrophy. Tumor necrosis factor alpha (TNF-α), dexamethasone, 
disuse, nutritional deprivation, ageing and chronic diseases stimulate greater protein 
degradation rates (catabolism) compared to protein synthesis leading to atrophy (87-91). 
Multiple anabolic and catabolic factors function through various pathways to regulate protein 
turnover in skeletal muscle. 
 
 
1. 6. 1. Glucocorticoid-induced muscle atrophy 
Glucocorticoid (GC) levels increase in many pathological conditions that are characterized by 
muscle atrophy such as sepsis, cachexia and starvation (92, 93). This suggests that muscle mass 
loss in such conditions can be triggered by GC. Treatment with GC induces the expression of 
gene markers of atrophy including atrogin-1 and MuRF1 (Muscle ring factor 1), and decreased 
myotubes diameter in vitro and reduces muscle mass in vivo (41, 94-97). In contrast, treatment 
with a GC receptor antagonist (RU-486) or muscle-specific deletion of the GC receptor 
attenuates muscle wasting in sepsis (98), cachexia and starvation (99), and severe insulinopenia 
(100). While GC is not required in atrophy-induced by disuse (101) and denervation (102), it 
can aggravate the effects of disuse on muscle mass (103). GC-induced muscle atrophy is 
characterised by increased protein degradation and decreased synthesis rates (104-106), that 
results in atrophy of fast-twitch type 2X and 2B muscle fibres, with less or no impact on type 
1 fibres (107, 108). Therefore, the susceptibility of fast twitch glycolytic fibres towards atrophy 
is higher than slow twitch oxidative fibres making muscle groups such as tibialis anterior (TA) 
muscles suitable to study GC-induced atrophy as they possess a high content of GC receptors 
(109). In the nucleus, GC receptors activate the expression of the gene, regulated in 
development and DNA damage response 1, which blocks mTOR, a positive regulator of protein 
synthesis. GC receptors also activate Krüppel-like factor 15 (KLF15) that stimulates protein 
atrophy pathways through FOXO1, MuRF1, atrogin-1 and branched-chain aminotransferase 2 
(BCAT2) as depicted in Figure 1.4 (109). Together, these mechanisms lead to increased protein 
degradation and hence reduced muscle mass (109). Furthermore, evidence suggests that GCs 
not only stimulate ubiquitin proteasome dependent proteolysis but also calcium-dependent 
(calpain) and lysosomal protein breakdown and autophagy (increased conversion of LC3-I to 
LC3-II) pathways (110). Dexamethasone, a synthetic GC, increases protein degradation and 
hence promotes muscle mass loss (111-114). Although the molecular pathways of GC-
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mediated muscle wasting have been investigated in detail, the molecular factors contributing 




Figure 1. 4. Crosstalk between catabolic and anabolic processes and how glucocorticoids 
induce atrophy by modulating different mechanisms (109).  
 
 
1. 6. 2. Fasting-induced muscle atrophy 
Muscle mass loss also occurs as an outcome of extended fasting and nutrition restriction (93). 
Again the rate of overall protein synthesis in muscle is reduced with increased degradation of 
cell proteins (115), predominantly the contractile proteins (115). The reduction in protein 
synthesis is due to reduced rates of translation and translation initiation (116, 117). Protein 
translation requires eukaryotic translation initiation factor 4E (eIF4E) which is inhibited by 
phosphorylation of the inhibitory eIF4E binding protein, 4EBP1 (118). The transcriptional 
profiling of rodent gastrocnemius muscles revealed mRNA levels of eIF4E remain constant 
while 4EBP1 increases in 24h fasted (119). This increased protein breakdown and muscle loss 
occurs prominently via activation of the ubiquitin-proteasome system (UPS), the autophagy-
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lysosomal system, suppression of pathways involved in protein synthesis (120) and increased 
activity of calpains (68). The key components of the UPS, atrogin-1 and MuRF1, increase 
dramatically in starvation-induced muscle atrophy (120). Furthermore, starvation-induced 
autophagosomal degradation leads to the lipidation of LC3-I to LC3-II, hence increasing LC-
II/LC3-I ratio (121). LC3 lipidation has been partly considered as a marker of autophagy in 
fasting mediated muscle loss. AMP-activated kinase-2-alpha (AMPKα2), a cellular energy and 
nutrient sensor, is activated in fasting and regulates autophagy, it is not necessary for LC3 
lipidation induction (121). Autophagy is regulated by adenosine monophosphate-activated 
protein kinase alpha (AMPKα) which responds to nutrient stress to maintain energy by 
activating through phosphorylation of multiple metabolic pathways. For example, activation of 
AMPKα increases p38 mitogen-activated protein kinase (p38 MAPK) activation. In addition 
to above pathways during nutrient stress, muscle proteolysis is accelerated through activation 
of apoptosis marker, caspase 3 (122) and calcium-activated cysteine proteases, calpains (123). 
How and whether these different pathways function synergistically to regulate and maintain 
muscle mass during fasting induced atrophy is unknown.   
  
 
1. 6. 3. Muscle wasting in Amyotrophic Lateral Sclerosis (ALS) 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease manifesting from 
motor neurone death and reduced muscle innervation. Patients exhibit progressive muscle 
weakness, atrophy and paralysis with death occurring usually within a few years of symptoms 
onset (124). Both upper and lower motor neurons degenerate in the brain, brainstem and spinal 
cord and symptoms typically progress rapidly. ALS is not entirely a motor neuron disease as 
non-cell autonomous toxicity leading to the death of motor neurons may be due to 
neuroinflammation and muscle degeneration as well (reviewed in (125).  
Different mechanisms such as protein aggregation, oxidative stress (OS), mitochondrial 
damage (MD), excitotoxicity and RNA dysmetabolism contribute to ALS pathogenesis. 
Mutations in the gene encoding superoxide dismutase 1 (SOD1), which encodes the free 
radical-scavenging enzyme Cu/Zn superoxide dismutase, cause nearly 20% of familial cases 
and 1–2% of all ALS cases (126, 127). Initially, SOD1 mutations were the only known genetic 
causes of ALS. However, mutations to a number of other genes, including those encoding 
transactive response (TAR) DNA binding protein 43 (TDP-43), vesicle-associated membrane 
protein-associated protein B (VAPB), fused in sarcoma (FUS) and valosin containing protein 
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(VCP/p97) have also been associated with disease pathogenesis (128-133). A limited range of 
pharmaceutical agents to help treat ALS are available. Riluzole is widely used but it can afford 
only 2-3 months of life span extension through reduction in glutamate toxicity (134), and 
recently identified edaravone is a free radical scavenger and an antioxidant that may help 
reduce some of the OS experienced in ALS pathology (135); however, the latter comes with 
number of deleterious side effects (135).  
A key detrimental outcome from ALS neurodegeneration and different pathologies is muscle 
mass loss resulting from motor neuron denervation. For many ALS patients, death ensues from 
respiratory insufficiency with a weakened diaphragm muscle. Motor neuron denervation has 
been studied in detail using the SOD1G93A mouse. There is a preferential loss of motor units 
primarily from fast-twitch, type 2B fibres with compensatory gradual re-innervation of type 
2A and 2X fibres (136). Hence, fast twitch muscles such as TA muscle are characterised by 
decreased fibre cross sectional area with fibre type shift from glycolytic 2B to 2X and 
subsequently to oxidative type 2A (136). An understanding of the upstream pathogenic 
pathways of ALS is incomplete and there is an unmet need to identify effective targeted therapy 
to alleviate disease symptoms of ALS.  Targeting muscles as a primary site for therapeutic 
intervention may be critical to help alleviate pathologies and disease progression (reviewed in 
(106)) 
 
1. 6. 4. Oxidative and Endoplasmic Stress in skeletal muscle atrophy 
Reactive oxygen species (ROS), highly reactive oxygen containing molecules, are produced as 
by-products of oxygen metabolism (137, 138).  When present at high, sustained levels, ROS 
can override the antioxidant defence system and cause OS (139). Moreover, increased ROS 
presence can damage most of the major organelles ultimately leading to mitochondrial 
dysfunction and DNA damage (139, 140) and has been observed in muscle atrophies (141-143). 
As SOD1 mutations were the first identified cause of familial ALS in 1993, OS stress has been 
an obvious candidate to explore in the pathogenesis of ALS. In SOD1G93A mice, where a 
glycine is replaced by an alanine amino acid, several dysfunctional changes in the early disease 
stage can be observed in motor terminals of the diaphragm muscle (144). Furthermore, in 
muscle-specific hSOD1 mutant mice, muscle fibres are thought to initiate early changes that 
lead to disease progression in SOD1 mutants. This is evident with skeletal muscles developing 
OS and neuromuscular junction (NMJ) defects and undergoing muscle fibre death (145) with 
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presynaptic machinery in the NMJ being first affected by OS (146). OS biomarkers are 
upregulated in sporadic ALS patients suggesting its role in pathogenesis. How OS and the 
molecular pathways involved lead to muscle mass loss with human SOD1 mutations is 
demonstrated in Figure 1.5. Mutation in SOD1 leads to accumulation of ROS that causes 
increased OS. Elevated ROS activates PGC1-α, which shifts fibre type and metabolism to a 
more oxidative phenotype. FoxO1 and nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) activate ubiquitin proteasome and autophagy lysosome pathways leading to 
muscle atrophy (80). Interestingly, OS not only increases ROS levels but can affect protein 
conformation and structure leading to the accumulation of abnormal proteins in ALS. For 
example, mutant SOD1 aggregation is mediated by oxidative modification of cysteine, while 
as wild type SOD1 hyper-aggregates upon oxidation (147, 148).  
 
Figure 1. 5. Summary of how SOD1G93A mutation mediated increase in production of 
reactive oxygen species causes muscle atrophy (80). 
 
The endoplasmic reticulum (ER) regulates proper folding, post-translational modification and 
trafficking of many transmembrane and secretory proteins (149). The build-up of unfolded or 
misfolded proteins within the ER leads to ER stress that is alleviated by a signalling mechanism 
known as the unfolded protein response (UPR). Generally, the physical interaction of ER 
stressors with ER chaperone immunoglobulin binding protein (Grp78/BiP) suppresses stress 
activation. However, the aggregation of misfolded proteins leads to binding to misfolded 
aggregates and activation of Grp78/BiP and protein disulphide isomerase (PDI) protein 
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expression. Altogether these cause downregulations of protein synthesis (148, 156)). PDI can 
facilitate the ER-associated degradation of misfolded proteins (150). Oxidants that produce 
ROS can disturb ER protein folding and induce ER stress. For example, 7-ketocholesterol, a 
major oxidation product of cholesterol induces UPR in macrophages and smooth muscle cells 
suggesting that ER stress is oxidative stress dependent (151, 152). On the other hand, 
disulphide bond formation and protein misfolding in ER could be a source of ROS and hence 
oxidative stress (153). In addition, CCAAT-enhancer-binding protein homologous protein 
(CHOP), a major pro-apoptotic factor of UPR can induce oxidative stress in ER by activating 
calcium kinases (154, 155). Following stress, the neuronal damage in SOD1G93A mutants and 
patients ensues protein handling dysfunction in ER (156, 157). The role of ER stress in ALS 
pathogenesis is based on findings that; 1) it was activated at pre-symptomatic age and further 
upregulated at the symptomatic stage; 2) ER stress-induced CHOP, a cell death signal and 
mediator of apoptosis in skeletal muscle; 3) type II fibres of highly glycolytic muscles 
demonstrated higher activation levels of ER stress; and 4) ER stress is specific to skeletal 
muscle (158). An overview of different pathways that contribute to ER stress and hence muscle 
atrophy is shown in Figure 1.6. For the development of effective therapeutic approaches against 
ALS, mechanisms underlying the initial pathological events need to be identified. As oxidative 
and ER stress in ALS pathogenesis is evident, targeted antioxidant treatments and therapies 
with minimal side effects could be a promising therapeutic approach.  




Figure 1. 6. Schematic of unfolded protein response (URP) and endoplasmic reticulum (ER) 
stress pathway and the anticipated role in skeletal muscle atrophy and weakness in ALS. In 
skeletal muscle, SOD1G93A mutation causes oxidative stress and protein misfolding leading to 
activation of ER stressors protein kinase RNA-activated-like ER kinase (PERK) and inositol-
requiring kinase 1-alpha (IRE1a).  Accumulation of misfolded proteins activates and 
upregulates Grp78/BiP and PDI protein expression. Continued and severe ER stress elicits 
apoptosis by ER stress-specific cell death signals, including CHOP and caspase-12, causing 
muscle atrophy (158). 
 
 
1. 7. Role and regulation of N-myc Downstream-Regulated Gene 2 (NDRG2) 
in skeletal muscle  
 
1. 7. 1. NDRG2 in Skeletal Muscle 
N-myc downstream-regulated gene 2 (NDRG2) together with NDRG1, NDRG3 and NDRG4, 
constitute the NDRG protein family that regulates proliferation, differentiation and stress 
responses in a range of cell and tissue types (159-161). They are highly conserved across 
phylogeny, as human NDRG2 displays 95% amino acid sequence similarity with the mouse 
homolog (162, 163). NDRG2 is primarily expressed in skeletal muscle heart, brain, with lower 
levels expressed in kidney and liver as well, which is depicted in Figure 1.7 (160, 164, 165). 
Moreover, Figure 1.7 obviously reveals that, out of 4 NDRG family members, NDRG2 is the 
most abundant protein in mature skeletal muscle. Protein expression analysis in embryonic and 
adult mouse tissues revealed that during the late embryonic period, the developing skeletal 
muscle exhibits strong NDRG2 protein expression in more mature skeletal muscle cells (166). 
NDRG2 has a non-functional α/β-hydrolase domain in the N-terminal region (162) and several 
potential phosphorylation sites in the C-terminal region containing consensus Akt 
phosphorylation sites (167, 168). Insulin-dependent phosphorylation regulates NDRG2 in 
skeletal muscle cells (168, 169).  Moreover, in skeletal muscle, NDRG2 is the substrate for a 
number of other serine-threonine protein kinases, including protein kinase theta and serum- 
and glucocorticoid-induced kinase 1 (168). Further to this, a phosphoproteome exploration of 
human skeletal muscle demonstrated that, out of 127 proteins identified, NDRG2 is highly 
phosphorylated (169). NDRG2 protein is linked to hereditary muscle wasting condition (170). 
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For instance, Limb girdle muscular dystrophy type 2H (LGMD2H) ensues as a consequence 
of mutations in TRIM32, the gene encoding the E3 ubiquitin ligase (171). To explore further 
the reasons for this, protein expression profiling revealed increased NDRG2 levels in TRIM32 
knockout (T32KO) mice compared to control counterparts. Furthermore, NDRG2 protein is 
thought to be a novel substrate for TRIM32 ubiquitination (170); however, this study did not 
establish whether the increased levels of NDRG2 contributed directly to the development of 
LGMD2H. To characterise the potential physiological role of NDRG2, NDRG2 knockout 
mouse models have been generated. While these studies have reported different potential 
functional roles for NDRG2 in vivo, such as in cancer formation and skeletal vertebrate 
development, none of the studies investigated specifically the loss or gain of NDRG2 in skeletal 
muscle development or function (172-175). To date, the expression of NDRG2 in muscle 
tissues is confirmed, while its function and role is largely unknown.   
 
Figure 1. 7. Gene expression of different members of the NDRG family in various tissues. 





1. 7. 2. Regulation of NDRG2 in skeletal muscle 
Since muscle mass is influenced by anabolic and catabolic stressors, NDRG2 mRNA 
expression was suppressed and induced in response to anabolic and catabolic signals, 
respectively in C2C12 myotubes (165). These findings indicate NDRG2 is responsive to 
different stress conditions within skeletal muscle cells and may play a protective role against 
muscle mass loss condition. In response to resistance exercise training, a hypertrophy causing 
signal, NDRG2 expression is reduced (176), while NDRG2 is induced following an acute bout 
of endurance exercise in humans (177). The information on mechanisms that regulate NDRG2 
in muscle is limited, however, a study by our group demonstrated that NDRG2 is a target of 
PGC1-α and estrogen-related receptor alpha (ERRα) transcriptional program and was induced 
by PGC1-α/ERRα transcriptional regulation in myotubes (177). This suggests NDRG2 could 
play a role in muscle mass maintenance through mitochondrial regulation under catabolic 
conditions. Moreover, NDRG2 suppression caused increased mRNA levels of fast glycolytic 
myosin heavy chain isoforms and reduced protein synthesis rates induced by ERRα (178).  
 
1. 7. 3. The in vitro function of NDRG2 in muscle cells 
Cell culture experiments in our laboratory have shown that NDRG2 expression is increased 
significantly during myoblast differentiation in both mouse and human models (176). The 
suppression of endogenous levels of NDRG2 reduced the proliferation of mouse C2C12 
myoblasts and increased the expression of the negative cell cycle regulators, p21 and p27, and 
of myogenin. This early exit from the cell cycle and induced myogenic regulatory factor (MRF) 
expression resulted in premature and abnormal myoblast differentiation (176). Conversely, the 
overexpression of NDRG2 promoted C2C12 myoblast proliferation but did not enhance overall 
myoblast differentiation (179). Further to this study, the other finding was that NDRG2 
overexpression protected C2C12 myoblasts against oxidative and ER induced stress by 
hydrogen peroxide treatment; however, it did not protect against palmitate induced lipotoxicity 
(179). In another study, through gene and protein expression profiling, various molecular 
pathways linked to muscle development, contractile function and metabolism following the 
knockdown of NDRG2 in C2C12 myotubes were identified (177). Here, NDRG2 suppression 
resulted in increased myotube protein synthesis and type 2 MHC gene expression, while 
overexpression decreased protein synthesis rates (177). Together, these findings suggest roles 
for NDRG2 in skeletal muscle growth, maintenance of muscle mass and protection against 
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stress situations. However, as all of the above findings were reported in in vitro model systems, 
in vivo confirmation of these observations remains to be determined. In addition, the molecular 
mechanisms that regulate NDRG2 in response to stress in skeletal muscle require elucidation. 
Taken together, the physiological role of NDRG2 is still unclear and investigating further its 
regulation and function will reveal whether it plays a role in maintaining muscle mass loss.   
 
 
1. 8. MicroRNAs  
The regulation of NDRG2 in skeletal muscle cells is unknown and microRNAs could play as 
the possible regulatory molecules. MiRNAs are short non-coding RNAs (∼22 nucleotides) that 
are involved in the post-transcriptional regulation of gene expression and are indispensable for 
development, physiology and metabolism (180-182). To date, thousands of miRNAs and their 
specific targets have been identified. MiRNA activity essentially depends on its binding 
capacity to the target mRNA molecule. Most binding sites are located in the 3’ untranslated 
region (UTR) of the target mRNA, however, some miRNAs bind to the 5’ UTR and within 
introns as well (154, 183, 184). Predominantly, miRNAs specifically inhibit protein expression 
either through the degradation of specific mRNA species or through the repression of protein 
translation (185-188) following complementary binding of the miRNA to its target mRNA 
(Figure 1.8). Following the development of algorithms and bioinformatic websites, such as 
miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) and TargetScan 
(http://www.targetscan.org/), have led to a greater understanding and prediction of 
miRNA/mRNA interactions (184, 189). These algorithms and others have estimated that as 
many as 60% of mRNAs are subject to miRNA-mediated regulation post-transcriptionally 
(190). Mostly, these programs are based on the concept that miRNA target recognition involves 
conserved Watson-Crick pairing or non-Watson–Crick or wobble base pairing (seen as G:U) 
to the 5’ region of the miRNA centered on nucleotides 2-7, which is known as the miRNA 
“seed region” and is depicted in Figure 1.9. As it has been established that a single miRNA can 
regulate multiple mRNAs and, conversely, multiple miRNAs can target single mRNA (191), 
determining which mRNAs are targeted by miRNA regulation is an important step to 
understand biological processes clearly. Targeting can occur in 5’ UTR, 3’ UTR and the open 
reading frame as well (192). By understanding features and the bioinformatic tools available, 





Figure 1. 8. Schematic representation of miRNA—mRNA interactions. (A) Complementary 
binding between miRNA and mRNA. Once bound to the mRNA molecule, the miRNA can 





Figure 1. 9.  Schematic overview of a miRNA interaction with its mRNA target (189). 
 
 
1. 8. 1. MicroRNAs as regulators of skeletal muscle 
MicroRNAs can be distinctly enriched in specific tissues (193) and skeletal muscle enriched 
miRNAs are referred as myomiRs, which include miR-1, miR-133a, miR-133b, miR-208, miR-
208b, miR-486 and miR-499 (194-198). The muscle-specific transcriptional activity of 
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myomiRs is regulated by muscle-related factors such as MRFs including MyoD, MyoG, Myf5 
and MRF4 (199, 200). Various biological processes involved in skeletal muscle growth and 
development, and in muscle mass and maintenance, modulate the specific expression of 
miRNAs in skeletal muscle (194, 201, 202). For example, a 50% decrease in the expression of 
miR-1 and miR-133a was reported in mouse plantaris muscle following hypertrophy-induced 
functional overload when compared to control muscle (203). It was proposed that these two 
miRNAs contribute to muscle hypertrophy by removing their transcriptional inhibitory effect 
on growth factors e.g. IGF-1; which was supported by in vitro analysis demonstrating that IGF-
1 downregulates miR-1 via the Akt/FoxO3a pathway. Moreover, it was shown that FoxO3a 
overexpression leads to increased miRNA levels and thereby lowering IGF-1 protein levels 
(204). Furthermore, the downregulation of Pax3 by miR-27 is essential for exiting the cell cycle 
and progress of myogenesis as it contributes to self-renewal capability of satellite cells (205). 
Conversely, miR-27 knockdown leads to delayed myogenic differentiation and sustained Pax3 
expression (205, 206). Yin Yang1 (YY1) is considered as a myogenic transcriptional repressor 
as it directly inhibits the synthesis of terminal differentiation genes, including α-skeletal actin, 
muscle creatine kinase, and myosin heavy chain IIb. MiR-29, as well as miR-214 and miR-26, 
target and suppress YY1, and therefore, promote muscle-specific gene expression and 
differentiation (207, 208). In addition, miR-181 increased expression promotes differentiation 
by suppressing homeobox A11 (HoxA11), a MyoD negative regulator, while decreased 
expression of miR- 221/222 activates p27kip1 and inhibits proliferation (209, 210). An 
overview of miRNAs that regulate genes involved in myogenesis is depicted in Figure 1.10. 
Furthermore, in 10 major muscular disorders in humans including Duchenne muscular 
dystrophy, Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle 
muscular dystrophies types 2A and 2B, Miyoshi myopathy, nemaline myopathy, polymyositis, 
dermatomyositis, and inclusion body myositis, miRNA expression profiling confirmed 185 
differentially expressed miRNAs. Out of these only five miRNAs (miR-146b, miR-221, miR-
222, miR-155, and miR-214) were constantly upregulated in most of these muscle dystrophies. 
Interestingly, none of these miRNAs included any muscle-enriched myomiRs (211). Other 
more ubiquitously expressed miRNAs, such as miR-23a, also bind to the 3’ UTRs of myosin 
heavy chains to inhibit myogenic differentiation (212). MiR-23a also is increased in 
dexamethasone-treated myotubes (213) and attenuates dexamethasone-induced muscle 
wasting potentially through the translational inhibition of the ubiquitin proteasomal E3 ligases, 
MAFbx/atrogin-1 and MuRF1 (214). While miRNA research in muscle development, health 
and maintenance has advanced over the past 10 years, the full comprehension of the 
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Figure 1. 10. MicroRNAs and their gene targets involved in muscle stem cell (MSC) cycle 
exiting and differentiation into myotubes. MyoD plays an important role through regulating 
the expression of the muscle-enriched miR-1, miR-133, and miR-206. Upregulation or 
downregulation of a specific miRNA is represented by an upward (black) or a downward 
(red) arrow, respectively. The changes in the expression levels of a target gene inversely 
correlate with that of the targeting miRNA and are similarly represented by an up or down 
arrow. Only the miRNA targets that have been specifically verified in skeletal muscle are 
listed. All listed targets have been validated. The listed targets include (HoxA11), paired box 
gene 3 (Pax3), DNA polymerase alpha catalytic subunit (DNA pola), serum response factor 
(SRF), zeste homolog 2 (Ezh2), ying and yang 1 (YY1), histone deacetylase 4 (HDAC4), and 
uncoupling protein 2 (UCP2) (215). 
 
 
1. 8. 2. MicroRNA regulation of NDRG2 
MircroRNAs regulate skeletal muscle growth, function, atrophy and show differential 
expression during multiple muscle diseases reviewed in (216). However, no study has been 
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undertaken to investigate whether miRNAs regulate NDRG2 in skeletal muscle although a 
number of studies have shown NDRG2’s regulation by miRNA in cancer cells. For example, 
NDRG2 is directly regulated by miR-650 and the expression is downregulated in colorectal 
(217) and breast cancer cells (218). Recently, in addition to miR-650, miR-28 targets and 
suppress human NDRG2 in chronic lymphocytic leukemia cells (219). Additionally, Hypoxia-
induced miR-301a/b in prostate cancer cells (220) (221) and miR-181c overexpression in 
cholangiocarcinogenesis and metastasis (222) target NDRG2 3’UTR and decrease its protein 
levels. Identifying miRNAs that could potentially regulate NDRG2 in skeletal muscle cells is 
important to understand how this gene functions to regulate myogenesis.  
 
 
1. 9. Establishing the Role of Specific Targets in Skeletal Muscle 
Development, Maintenance and Function 
 
Viral vectors are effective gene delivery platforms for the treatment of genetic and acquired 
diseases as many provide the long-term expression of the target gene, as well as to characterize 
the role of genes both in vivo and in vitro. Different viral systems have been established to 
study skeletal muscle development, function and to attempt the treatment of various muscle 
diseases as reviewed in (223). Muscle gene therapy displays potential for a variety of 
applications ranging from treatment of muscular dystrophies to systemic delivery of therapeutic 
proteins with adeno-associated virus (AAV) vectors currently leading the way in this field as 
they are safe and do not integrate into the host genome. Alternatively, lentiviral vectors (LTVs), 
with their ability to transduce satellite cells and other muscle cell progenitors, may have an 
advantage over more episomal-based delivery systems such as AAV (224-226). Importantly, 
AAVs and LTVs have become indispensable tools to understand and characterise the function 
of specific genes in skeletal muscle in vivo.    
 
 
1. 9. 1. Adeno associated viruses (AAVs) 
Currently, AAV vectors are among the most regularly used viral vectors for gene therapy. 
AAVs can transduce both dividing and non-dividing cells efficiently in a wide range of tissues 
and do not elicit a strong immune response (227). Throughout infection, the virus vector 
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genomes go into the cell nucleus, where it remains in several molecular states. While it has 
been reported to integrate into the host cell’s genome, the primary state is the conversion of the 
AAV genome into circular episomal double-strands using complementary strand pairing (228-
230). These episomal double-strands can be converted to concatamers, which are high 
molecular weight tandem repeats (231, 232). These multimeric units provide continuing 
transgene expression, predominantly in non-dividing cells (233-236). To date, almost 13 AAV 
serotypes have been discovered and these show variety of tissue tropisms and binding 
characteristics to infect many tissues efficiently, including the liver (237), lung (238), and 
skeletal muscle (239, 240). AAV serotype 1, 2, 6, 8 and 9 provide efficient in vivo gene transfer 
in myofibres at various stages of maturity, making AAV a promising vector system for injured 
and pathological muscle tissue (241). Despite efficient transduction in different tissues, AAVs 
are restricted in their ability to deliver small genes that are up to 4 kb in size. This size limitation 
is due to the small packaging capacity of AAV capsid (227). To overcome this limitation, 
researchers have tried to delete less important genes from the transgene or alternatively break 
large genes into smaller fragments and package each individual piece into separate AAV 
viruses (242-247). On the other hand, recent studies demonstrated that some AAVs do not 
transduce muscle satellite cells very efficiently, such as serotype 6 (248), or have limited 
infection efficiency in primary and more immortal cultured myoblasts as seen with some AAV 
serotypes (249). Therefore, AAV transduction is an important option for efficient virus-
mediated gene delivery into the mature skeletal muscle with few side effects. 
  
   
1. 9. 2. Lentiviruses (LTVs) 
Lentiviruses are a class of retroviruses with the distinctive capability of infecting both dividing 
and non-dividing cells including skeletal muscle cells. Further, this ability has led to their 
development as gene delivery vehicles (250, 251). Additionally, unlike other retroviruses, the 
lentiviral pre-integration complex is transported actively through the nucleopore by the nuclear 
import machinery of the target cell, and is incorporated into host genome (252).  In skeletal 
muscle, pseudotyped lentiviral vectors were used to encode a minidystrophin gene and, 
progenitor cells were successfully genetically engineered in vivo and proliferated into 
terminally differentiated muscle tissue (226). The tibialis anterior (TA) muscles of neonatal 
mdx mice, a mouse model of human DMD, displayed long-term, but not widespread, 
expression of the LTV in muscle satellite cells and mature myofibres following intramuscular 
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injection (253). Other advantages of LTVs include their capacity to package large genes up to 
9 kb, in addition to providing long-term transgene expression in growing, damaged, or diseased 
muscle (254). Together, AAV and LTVs represent key tools to study gene function in both 
developing and mature skeletal muscle under both healthy and stressed or diseased conditions. 
 
1. 1. 1. Summary 
Skeletal muscle in an important tissue that performs vital functions for the body. Maintaining 
healthy skeletal muscle is imperative for normal functioning and adaptations to acute stress and 
injury. Skeletal muscle develops during postnatal life largely through the process of 
hypertrophy. Normal development during the early postnatal period is essential for normal 
muscle development in later life and any defect in it can permanently affect later muscle growth 
and function. Hence, a clear understanding of the regulation of postnatal myogenesis is 
important for muscle development. Skeletal muscle is sensitive to different stresses and 
maintains itself through adult myogenesis. In addition, muscle stressors influence skeletal 
muscle mass via regulating protein turnover and fibre size control or shift cause atrophy 
(catabolic stress) or hypertrophy (anabolic stress). MicroRNAs have the potential to improve 
our understanding of the underlying molecular mechanisms regulating skeletal muscle atrophy 
and hypertrophy. A number of miRNAs are involved in healthy skeletal muscle development, 
regeneration and maintenance. It is therefore imperative that further research is made in 
understanding muscle development, maintenance and health to improve quality of life.  
 
NDRG2, a stress responsive gene, is up- and down-regulated by catabolic and anabolic 
stressors in mouse C2C12 myotubes and by endurance and resistance exercise effects in human 
muscle, respectively. Its overexpression increases the proliferation of C2C12 myoblasts, and 
interestingly, reduces protein synthesis rates in C2C12 myotubes. NDRG2 protects muscle 
cells against H2O2-induced stress, a stress that causes both oxidative and ER stress. Another 
study reported NDRG2 as a substrate for TRIM32 ubiquitination, linked with LGMD. 
Although these roles of NDRG2 are known in skeletal muscle cells, how NDRG2 is regulated 
and how NDRG2 regulates these processes is not completely known. The majority of the above 
findings, regarding NDRG2, were reported in in vitro model systems. Whether the 
overexpression of NDRG2 in vivo will help protect muscle mass under different stress 
conditions remains to be elucidated. Therefore, to understand further the molecular 
mechanisms regulating NDRG2 in muscle cells, this thesis will explore miRNA regulation of 
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NDRG2 under normal and catabolic stress conditions in C2C12 myotubes following 
dexamethasone treatment. Next, to test whether NDRG2 can contribute to the increase muscle 
mass during postnatal myogenesis or help catabolic stress in vivo, NDRG2 will be 
overexpressed in skeletal muscle using either an AAV or LTV virus systems in newborn, or 
adult fasted mice and in the mouse model of ALS, SOD1G93A transgenic mice. Altogether, these 
studies will further the understanding of NDRG2 regulation in muscle and characterise its role 
in actual physiological conditions in skeletal muscle under different catabolic conditions.               
 
 
1. 1. 2. Aims and hypothesis 
This PhD thesis will investigate and identify miRNAs that regulate NDRG2 under basal and 
catabolic stress conditions in muscle myotubes. In addition, to extend previous in vitro findings 
the thesis will investigate whether NDRG2 overexpression in vivo protects skeletal muscle 
from various stress during acute fasting and chronic disease conditions. Therefore, the working 
hypothesis of this thesis is that NDRG2 will protect mouse skeletal muscle during chronic and 
acute stress conditions by modulating stress responsive pathways. Furthermore, it is 
hypothesized that muscle-enriched miRNAs are novel regulators of NDRG2 expression 
 
 
1. 1. 2. 1. Specific Aims  
1. To identify and determine whether miRNAs predicted through an in silico approach will 
regulate NDRG2 expression during basal and catabolic stress conditions in muscle cells.  
 
2. To compare two separate viral approaches to overexpress mouse NDRG2 specifically in the 
striated muscle of mouse neonates in vitro and in vivo. If successful, the effect of muscle-
specific NDRG2 overexpression on postnatal muscle development would be measured.  
 
3. To determine if NDRG2 overexpression altered muscle mass and or stress response 
pathways in skeletal muscle under basal and fasting conditions.  
 
4. To investigate whether NDRG2 overexpression alleviated oxidative and ER stress levels in 





1. 1. 2. 2. Specific Hypotheses 
Aim 1. The working hypothesis for this aim is that predicted miRNAs will regulate the 
expression of NDRG2 in skeletal muscle under basal and/or catabolic stress conditions. 
MicroRNAs will target NDRG2 mRNA and inhibit its protein translation and hence its 
downregulation. These miRNAs will target 3’-UTR of NDRG2 directly to regulate its function. 
 
Aim 2. It is hypothesised that the AAV or LTV viral vector system will overexpress NDRG2 
specifically in striated muscle increasing postnatal muscle cell growth confirming an in vivo 
role for NDRG2 in myogenesis.  
  
Aim 3. NDRG2 expression increases in response to catabolic conditions in skeletal muscle. 
Therefore, it is hypothesised that NDRG2 overexpression will alter muscle’s adaptive response 
to fasting and impact signalling pathways that regulate muscle mass.  
 
Aim 4.  NDRG2 overexpression protects myoblasts against H2O2 induced oxidative stress in 
vitro. In this study, it is hypothesised that the overexpression of NDRG2 will attenuate 
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2. 0. MicroRNA suppression of stress-responsive NDRG2 during 
dexamethasone treatment in skeletal muscle cells 
 
Bilal Ahmad Mir, Rabia Islam, Ming Kalanon, Aaron P. Russell and Victoria C. Foletta1,  
Deakin University, Geelong, Australia, Institute for Physical Activity and Nutrition (IPAN), 
School of Exercise and Nutrition Sciences. 
 
2. 1. Abstract 
MicroRNAs (miRNAs) are increasingly being identified as modulatory molecules for 
physiological and pathological processes in muscle. Here, we investigated whether miRNAs 
influenced the expression of the stress-responsive gene N-myc downstream-regulated gene 2 
(Ndrg2) in skeletal muscle cells through the targeted degradation or translation inhibition of 
Ndrg2 mRNA transcripts. Three miRNAs, mmu-miR-23a-3p (miR-23a), mmu-miR-23b-3p 
(miR-23b) and mmu-miR-28-5p (miR-28), were identified using an in silico approach and 
confirmed to target the 3’ untranslated region of the mouse Ndrg2 gene through luciferase 
reporter assays. However, miR-23a, -23b or -28 overexpression had no influence on NDRG2 
mRNA or protein levels up to 48 h post treatment in mouse C2C12 myotubes. Interestingly, a 
compensatory decrease in the endogenous levels of the miRNAs in response to each other’s 
overexpression was measured. Furthermore, dexamethasone, a catabolic stress agent that 
induces NDRG2 expression, decreased miR-23a and miR-23b endogenous levels at 24 h post 
treatment suggesting an interplay between these miRNAs and NDRG2 regulation under similar 
stress conditions. Accordingly, when overexpressed simultaneously, miR-23a, -23b and -28 
attenuated the dexamethasone-induced increase of NDRG2 protein translation but did not 
affect the expression of Ndrg2 mRNA. These findings highlight modulatory and co-regulatory 





2. 2. Background 
MicroRNAs (miRNAs) are small non-coding RNAs implicated as post-transcriptional 
regulators of fundamental skeletal muscle biological processes. Changes in their expression 
during muscle cell differentiation (209, 255, 256) and in response to stress and exercise (203, 
257, 258), have resulted in the identification of miRNAs contributing to the control of muscle 
cell proliferation, tissue development, muscle regeneration and homeostasis (47, 209, 255, 259-
261). MiRNAs may function through binding to specific regions of the 3′ untranslated region 
(3’UTR) of genes causing mRNA degradation or translational repression. For example, miR-
23a binds to the 3’UTRs of fast myosin heavy isoforms contributing to the inhibition of 
myogenic differentiation (262). MiR-23a also inhibits the translation of muscle-specific 
ubiquitin ligase genes, MAFbx/atrogin-1 and MuRF1, to protect against glucocorticoid 
dexamethasone-induced skeletal muscle atrophy (214). Increased miR-181 expression 
enhances differentiation by suppressing homeobox protein HOX-A11, a MyoD negative 
regulator (209). Other miRNAs and muscle-specific miRNAs (myomiRs) are implicated in the 
control of skeletal muscle atrophy and hypertrophy processes (258, 263), myogenesis (264) 
and muscle-specific diseases (reviewed in (265)). While a number of miRNAs have been linked 
to the modulation of biological processes and stress responses in skeletal muscle, the genes 
they target to effect these changes are not well characterised.   
N-myc downstream-regulated gene 2 (NDRG2) is a stress-responsive member of the NDRG 
family involved in preventing tumour growth and invasion (reviewed in (161)).  MiR-650 
directly regulates NDRG2 and its upregulation is inversely associated with decreased NDRG2 
expression in colorectal (217) and breast cancer cells (218). Hypoxia-induced miR-301a/b 
targets the 3’UTR of Ndrg2 resulting in NDRG2 protein suppression and increased autophagy 
and viability of prostate cancer cells (220, 221). MiR-181c overexpression binds Ndrg2’s 
3’UTR and downregulates its protein levels during cholangiocarcinogenesis and metastasis 
(222). NDRG2 is also involved in a double-negative regulatory loop between leukemia 
inhibitory factor (LIF)/miR-181c where NDRG2 acts to inhibit LIF induction of miR-181c 
(222).  In adrenocortical carcinoma cells, miR-483-5p targets and suppresses NDRG2 to 
promote cancer invasion and pathogenesis (266). Together, these studies highlight the interplay 
between miRNAs and NDRG2 function in cancer cells. There is currently very limited 
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information regarding the regulation of NDRG2 by miRNAs in well-differentiated cell types 
such as skeletal muscle.   
NDRG2 is highly expressed in skeletal muscle (164) with expression increasing during muscle 
differentiation and development in vitro (176) and in vivo (166). In muscle cells, NDRG2 
promotes myoblast proliferation and protects against oxidative stress (179). It is potentially 
associated with muscle mass changes where its expression is down and upregulated under 
anabolic and catabolic conditions, respectively, following dexamethasone treatment or 
resistance training (176). The molecular factors regulating NDRG2 expression levels during 
myogenesis and in response to stress are poorly defined. While the mouse Ndrg2 gene was 
identified as a target of the peroxisome proliferator-activated receptor-gamma coactivator-
1alpha and estrogen-related receptor alpha transcriptional program (177), a role for miRNA 
regulation of NDRG2 in skeletal muscle cells is currently unknown. 
In this study, miRNA prediction software and literature analysis were used to identify possible 
miRNAs that target the Ndrg2 gene. Luciferase assays confirmed interactions of the predicted 
miRNAs with the mouse Ndrg2 3’UTR. The modulation of endogenous mRNA and protein 
levels of NDRG2 under basal and dexamethasone stress conditions following individual or 
combined miRNA overexpression was investigated in C2C12 myotubes.  
 
2. 3. Materials and Methods 
2. 3. 1. MicroRNA target prediction using in silico approaches 
microRNA.org (151, 186) and miRWalk2.0 (267) softwares identified miRNAs predicted to 
target the 3’UTR region of mouse Ndrg2 (NM_013864). To note, all mouse Ndrg2 variants 
have the same 3’UTR (https://www.ncbi.nlm.nih.gov/gene/29811). microRNA.org uses 
miRanda-predicted target sites with mirSVR scoring (151), and the miRWalk2.0 program 
enables the prediction of miRNA targets using a combination of the software programs: 
miRanda; miRWalk; RNA22; and Targetscan. MicroRNAs that were both predicted by 
microRNA.org and by all four software components of miRWalk2.0 were considered further. 
From these miRNAs, only those with a mirSVR score of -0.7 to -1.0 and an association with 





2. 3. 2. Dual luciferase reporter assay 
The full length 868 bp 3’UTR fragment of the Ndrg2 mRNA containing predicted miRNA 
binding sites was amplified by RT-PCR. The 3’UTR product was cloned downstream of the 
NanoLuc luciferase (Nluc) gene coding region in the pmirNanoGLO2 vector, which also 
contains the firefly luciferase (luc2) reporter gene for normalisation (Promega, Alexandria, 
NSW, AUS). The oligonucleotides designed to encompass the Ndrg2 3’UTR seed sequences 
for the predicted miRNA binding sites and their mutated equivalents are listed in Table 2.1. 
Approximately 1 x 105 HEK293 cells (ATCC) were plated in 96-well white-walled plates. The 
following day, 150 ng of each plasmid and 5 nM of each miRNA were co-transfected using 
Lipofectamine 2000 and Opti-MEM I reduced serum medium (Life Technologies, Mulgrave, 
VIC, AUS) as described by the manufacturer. Four hours post-transfection, the transfection mix 
was removed and replaced by growth medium containing 25 mM glucose Dulbecco’s Modified 
Eagle Medium (DMEM) with 10% fetal bovine serum. Twenty-four or 48 h later, cells were 
consecutively assayed for Nanoluc and Firefly luciferase expression using the Nano-Glo® 
Dual-luciferase® Reporter assay kit (Promega) following the manufacturer's protocol. 
Normalized relative luciferase activity (RLA) was calculated as the following formula: RLA = 
[Nluc]/[luc2 luciferase]. To note, C2C12 myoblasts were also assessed but HEK293 cells were 
consistently more reliable with their signal output and sensitivity than following transfection 
of the C2C12 myoblasts. 
 
Table 2. 1. Oligonucleotide sequences used for cloning of mNdrg2 3’UTR, the predicted 
miRNA seed sites or their scrambled mutated versions. Restriction sites are indicated in bold 
and seed sequence regions are underlined. 














2. 3. 3. Cell Culture and miRNA transfections 
Mouse C2C12 myoblasts (ATCC, Manassas, VA, USA) were cultured in growth medium at 
37 °C in 5% CO2. To differentiate cells, medium consisting of 2% horse serum and 25 mM 
glucose DMEM was added when cells were confluent and refreshed every 48 h over a 6 day 
period. The miRNAs, mmu-miR-28-5p, mmu-miR-23a-3p, mmu-miR-23b-3p, mmu-miR-
181a-5p or negative control (NC) miRNA (mirVana® miRNA mimics; Thermo Fisher 
Scientific, Scoresby, VIC, AUS) were transfected at 5 nM into differentiated myotubes using 
Lipofectamine 2000 and Opti-MEM I reduced serum medium (Life Technologies) as 
recommended. Myotubes were collected at 12, 24, or 48 h post transfection for Ndrg2 mRNA 
analyses and for NDRG2 protein assessment. For mixed miRNA transfections, 5 nM of the 
three miRNAs were each combined together and transfected into myotubes with comparison 
to 15 nM NC miRNA transfected samples. For catabolic treatments, 10 µM dexamethasone 
(Sigma-Aldrich, Castle Hill, NSW, AUS) or 0.1% dimethyl sulfoxide (DMSO) vehicle were 
added to myotubes up to 48 h post-transfection and harvested concurrently. 
 
2. 3. 4. RNA extraction and gene expression analysis 
Total RNA was isolated using Tri-Reagent (Ambion Inc, Austin, TX, USA), treated with 
DNAse I and RNase H (Life Technologies), and quantitated using the NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific). Half a microgram of RNA was reverse-
transcribed to form cDNA using the High Capacity cDNA reverse transcription kit (Applied 
Biosystems, Foster City, CA, USA) according to manufacturer’s instructions. Semi-
quantitative polymerase chain reaction (qPCR) was performed using the Mx3000 PCR system 
(Stratagene, La Jolla, CA, USA) with SYBR Green Master Mix (Applied Biosystems). The 
qPCR cycling conditions were: 95°C for 10 min (1 cycle), 30 s at 95°C and 60°C for one min 
(40 cycles). Primers for mouse Ndrg2 (NM_013864.2; forward 5’cccacacagacctcgttcc and 
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reverse 5’gccatcgatggatgctgca) and a housekeeping gene, 36B4/Rplp0 (NM_007475.5; forward 
5’ttgtgggagcagacaatgtg and reverse 5’agtcctccttggtgaacacg), were synthesized by GeneWorks 
(Adelaide, SA, AUS). To note, the primers for Ndrg2 will detect all known variants of mouse 
Ndrg2. Samples were measured in duplicate using the Stratagene Mx3000P qPCR thermal 
cycler (Agilent Technologies, Mulgrave, VIC, AUS) and MxPRO qPCR software (Agilent 
Technologies). The relative gene expression is expressed as arbitrary units, which was 
calculated using the 2−ΔCt formula following normalization to 36B4 cycle threshold (Ct) levels. 
 
2. 3. 5. Western blotting 
Cells were lysed in 1× modified RIPA buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.25% 
deoxycholic acid, 1% NP-40, 1 mM EDTA) (Merck Millipore, North Ryde, NSW, AUS) 
containing dilution of 1:1000 protease inhibitor cocktail (Sigma-Aldrich) and 1:100 HALT 
phosphatase inhibitor cocktail (Thermo Fisher Scientific). Protein lysate concentrations were 
determined using Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific). Ten or twenty 
micrograms of protein lysates were electrophoresed on either 10% SDS–PAGE gels and 
transferred to Immobilon®-FL polyvinylidene difluoride membrane (Merck Millipore, Kilsyth, 
VIC, AUS). Membranes were blocked in 5% BSA for 1 h before incubation at 4°C overnight 
in primary antibodies diluted in 5% BSA/PBS. Rabbit polyclonal anti-NDRG2 antibodies 
(HPA002896; 1:5000) were obtained from Sigma-Aldrich. Rabbit monoclonal anti-α-tubulin 
(clone DM1A; 1:5000) was obtained from Abcam (Cambridge, MA, USA). The detection of 
proteins was performed using goat anti-rabbit AlexaFluor®680 or donkey anti-mouse 
AlexaFluor®800 IgG antibodies (Life Technologies) diluted at 1:10,000 in 50% Odyssey 
blocking buffer (Li-COR Biosciences, Lincoln, NE, USA), 50% PBS and 0.01% SDS. 
Membranes were imaged using the infrared imaging system (Li-COR Biosciences). Proteins 
were normalized against α-tubulin protein levels using the Li-COR software. 
 
2. 3. 6. Detection of miRNA expression 
MiRNA levels were measured by qPCR using specific primer and probes sets and the Taqman 
Universal MasterMix II, no UNG, kit as per the manufacturer’s instructions (Applied 
Biosystems, Carlsbad, CA). For miRNA expression analyses, total RNA (50 ng) was reverse 
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transcribed using the Taqman microRNA Reverse Transcription (RT) kit (Applied Biosystems). 
A customized RT primer pool was prepared by pooling all miRNA-specific stem-loop primers. 
In brief, miRNA-specific primers (TaqMan® MicroRNA assay kits, Life Technologies) were 
pooled and diluted in nuclease free water to obtain a final dilution of 0.05x each in a volume 
of 15 μl containing 2 mM dNTP, 10U enzyme, 1× RT buffer, 4U RNase inhibitor and 50 ng of 
total RNA. The reaction mix was reverse transcribed using the following conditions: 30 min at 
16°C, 30 min at 42°C and 5 min at 85°C. The qPCR conditions consisted of 1 cycle of 10 min 
at 95oC; 40 cycles of 15 s at 95oC, 60 s at 60oC. The TaqMan™ microRNA snoRNA202 
Control Assay was used as a normalizing control. Samples were run in triplicate for all miRNA 
targets and analysis was performed using the Stratagene MX3000P thermal cycler and 
dedicated software. 
 
2. 4. Statistics  
All data are reported as the mean ± standard error of the mean. Statistical differences were 
assessed using an unpaired Student’s t-test for two-group comparisons at each time-point. For 
data involving three or more groups, data were subjected to one-way ANOVA with a Dunnett’s 
or Sidak’s multiple comparison test performed if a significant difference was found. Analyses 
were performed using GraphPad Prism (GraphPad Software version 7, La Jolla, CA, USA). 
Data were considered statistically significant if p<0.05. 
 
2. 5. Results 
 
2. 5. 1. miR-23a, -23b and -28 bind and inhibit the translation of Ndrg2 
3’UTR 
 
Using an in silico approach, 16 miRNAs were initially predicted by both microRNA.org and 
miRWalk2.0. Following further consideration of their mirSVR score (151) and whether they 
had reported associations with skeletal muscle biological processes in the literature, three 
miRNAs; mmu-miR-23a-3p (miR-23a), mmu-miR-23b-3p (miR-23b), and mmu-miR-28-5p 
(miR-28), remained as predicted to bind to the murine Ndrg2 3’UTR with both miR-23a and -
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23b binding to the same seed site (Figure  2.1A-B).  To confirm whether these miRNAs targeted 
Ndrg2 3’UTR in vitro, luciferase assays revealed miR-23a, -23b or -28 overexpression 
decreased Ndrg2 3'UTR-luciferase reporter activity by 30%, 35% and 44%, respectively 
(Figure 2.1C). To check the validity of our selection criteria, mmu-miR-181a-5p (miR-181a) 
was also compared, which did not fit all the selection criteria. MiR-181a is associated with age-
related muscle atrophy through binding to the Sirt1 gene (268), and was predicted to bind to 
Ndrg2 3’UTR in microRNA.org (mirSVR score of -1.0372). However, miR-181a was not 
identified using miRWalk2.0, and its overexpression had no impact on Ndrg2 3'UTR-luciferase 
reporter activity (Figure 2.1C). To confirm the sites of interaction for the 3 miRNAs within the 
mouse Ndrg2 3'UTR region, luciferase assays were repeated using sequences containing the 
predicted seed site domains for miR-23a/-23b and miR-28 binding. MiR-23a, -23b, and -28 
overexpression each significantly reduced luciferase activity by 22%, 26% and 17%, 
respectively, indicating an ability to bind to their respective seed sites. The reductions in 
luciferase activity were blocked when the miR-23a/-23b or miR-28 seed sequences were 
mutated to prevent miRNA binding (Figure 2.1D-E). 
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Figure 2. 1. Selection and validation of predicted miRNAs binding to the mouse Ndrg2 
3’UTR. (A) Venn diagram of miRNAs predicted from miRWalk2.0 and microRNA.org 
algorithms, and selection criteria used to identify potential miRNAs binding Ndrg2 3’UTR. 
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(B) Nucleotide sequence alignment between the seed sites in the Ndrg2 3’UTR and predicted 
miRNAs with their corresponding mirSVR scores. (C) Dual-luciferase reporter assays 
determining the interaction of overexpressed miR-23a (dark grey bar), -23b (light grey bar), -
28 (white bar), -181a (striped bar) and negative control  (NC, black bar) with full-length 
Ndrg2 3’UTR; (D), with the miR-23a/-23b seed site (miR23seed) or its mutated version 
(miR23mut); and (E), with the miR-28 seed site (miR28seed) or its mutated version 
(miR28mut). Data is representative of three independent experiments with n=5-6 per sample 
group, and expression levels are presented as arbitrary units (AU). **p<0.01 and 
****p<0.0001 to NC. 
 
2. 5. 2. MicroRNA overexpression effects on endogenous NDRG2 mRNA and 
protein levels 
 
MiR-23a, miR-23b and miR-28 were overexpressed in C2C12 myotubes to evaluate if they 
could inhibit endogenous NDRG2 levels. Significant miRNA overexpression was achieved at 
each time point when compared to the respective negative control group (Appendix Figure 1), 
which was included for each time point as it was noted that Ndrg2 gene expression changed 
transiently in response to transfection effects. No change in Ndrg2 mRNA levels was measured 
at 12, 24 or 48 h following miR-23a or -23b overexpression (Figure 2.2A-B); however, Ndrg2 
mRNA expression was reduced by 20% (p<0.05) and 29% (p=0.018) at 6h post miR-23a 
(Figure 2.2A) and 24 h post miR-28 transfection (Figure 2.2C). Furthermore, no decrease in 
NDRG2 protein levels at any time point following transfection of either of the three miRNAs 
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Figure 2. 2. Impact of miRNA overexpression on endogenous mRNA and protein levels of 
NDRG2 under basal conditions. Time-course in hours (h) of Ndrg2 mRNA expression 
following transfection of (A) miR-23a (dark grey bar), (B) miR-23b (light grey bar), and (C) 
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miR-28 (white bar) compared to negative control (NC) miRNA (black bar). NDRG2 protein 
levels at (D) 12 h, (E) 24 h and (F) 48 h post miRNA transfection. Data are representative of 
two to three independent experiments with n=3-4 per sample group, and expression levels are 
presented as arbitrary units (AU). *p<0.05 and **p<0.01 to NC per respective time point. 
 
2. 5. 3. Regulation of endogenous miR-23a, -23b or -28 levels following 
miRNA overexpression or dexamethasone treatment in C2C12 myotubes 
 
As the overexpression of miR-23a, -23b or -28 did not reduce NDRG2 protein levels, next it 
whether miRNA overexpression could potentially compensate for each other reducing their 
ability to inhibit NDRG2 expression was investigated. MiRNA cooperativity and redundancy 
in biological processes is evident in C. elegans worm studies (269, 270) and in cardiac muscle 
tissue where multiple miRNAs may be required to target a common gene in order to regulate a 
biological process (reviewed in (271)). Unexpectedly, it was observed that miR-23a 
overexpression in myotubes resulted in the significant downregulation of endogenous miR-23b 
and -28 levels at 12 h post transfection (Figure 2.3A-B). Similarly, miR-23b overexpression 
reduced endogenous miR-23a levels significantly at 12 h (Figure 2.3C) and miR-28 (p<0.08) 
at 6 h (Figure 2.3D). Furthermore, miR-28 overexpression decreased endogenous miR-23a at 
12 h and reduced miR-23b levels at 24 h post transfection (Figure 2.3E-F).  
 
A catabolic stress condition known to upregulate NDRG2 (176, 272) was next introduced. It 
has also been reported that this catabolic stress, the glucocorticoid dexamethasone, decreases 
miR-23a levels in C2C12 myotubes 48 h post treatment (213). Here, this study also observed 
a downregulation of miR-23a, but at 24 h, not 48 h post dexamethasone treatment (p<0.05; 
Figure 2.4A). In addition, miR-23b expression levels were decreased 24 h post treatment which 
was not sustained at 48 h (p<0.001; Figure 2.4B). No significant regulation by dexamethasone 
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Figure 2. 3. miRNA overexpression downregulates endogenous miR-23a, -23b and -28 
levels. Endogenous miRNA levels over time (h) following miRNA overexpression.  (A) 
Endogenous miR-23b and (B) miR-28 levels following miR-23a overexpression (dark grey 
bar).  (C) Endogenous miR-23a and (D) miR-28 levels following miR-23b overexpression 
(light grey bar). (E) Endogenous miR-23a and (F) miR-23b levels following miR-28 
overexpression (white bar). Data are representative of two independent experiments with n=4 
per sample group; *p<0.05 and **p<0.01 to the negative control (NC; black bar) per 




Figure 2. 4. Endogenous miRNA levels following dexamethasone treatment. (A) 
Endogenous miR-23a, (B) miR-23b, (C) miR-28, and (D) snoRNA202 levels over time (h) 
following 10 µM dexamethasone (Dex) treatment. Data are representative of two independent 
experiments with n=4 per sample group; *p<0.05 and ***p<0.001 to control (DMSO) treated 
group per respective time point. Expression levels are presented as arbitrary units (AU).  
 
2. 5. 4. Combined overexpression of miR-23a, -23b and -28 blocks NDRG2 
induction during catabolic stress conditions 
  
As endogenous miR-23a, -23b and -28 levels were reduced by the overexpression of each other, 
and miR-23a and -23b decreased with dexamethasone treatment, these findings suggest an 
interplay between the three miRNAs and also with Ndrg2’s stress-response regulation by 
dexamethasone as reported by ourselves and others previously (176, 272).  Indeed, the increase 
in the miRNAs in response to dexamethasone could indicate a role for modulating NDRG2’s 
46 
 
stress-response. A cocktail mix of the three miRNAs was transfected into myotubes to 
determine if their combined overexpression could regulate NDRG2 levels in the presence or 
absence of dexamethasone. Transfection of the miRNA cocktail mix achieved significant 
overexpression of miR-23a, -23b and -28 in myotubes (Appendix Figure 2); however, no 
change was observed in Ndrg2 mRNA or NDRG2 protein levels under basal conditions (Figure 
2.5A-B). In the presence of dexamethasone, Ndrg2 mRNA and NDRG2 protein levels 
increased by approximately 100% and 20%, respectively, in C2C12 myotubes (Figure 2.5C-
D). While no impact on Ndrg2 mRNA expression was measured (Figure 2.5C), the combined 
overexpression of the three miRNAs blocked the dexamethasone-induced increase in NDRG2 
protein levels (p=0.0012; Figure 2.5D).     
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Figure 2. 5. The effect of combined miRNA overexpression on endogenous NDRG2 mRNA 
and protein levels under basal and catabolic conditions. miR-23a, -23b and -28 were co-
transfected into myotubes and their combined effects on NDRG2 regulation was measured in 
the presence or absence of 48 h treatment with 10 µM dexamethasone. (A) Ndrg2 mRNA and 
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(B) NDRG2 protein levels under basal conditions following miRNA co-treatment (striped 
bar) or negative control miRNA (NC, black bar) transfection. (C) Ndrg2 mRNA and (D) 
NDRG2 protein levels following the combined effects of DMSO vehicle and negative control 
miRNA treatment (Veh+NC; grey bar), dexamethasone and negative control miRNA 
treatment (Dex+NC; stippled bar), or dexamethasone and miRNA mix treatment (Dex+MM; 
cross-hatched bar). Data are representative of two independent experiments with n=4 per 
sample group, and expression levels are presented as arbitrary units (AU). *p<0.05, **p<0.01 
or p<0.001 to Dex+NC treatment and ***p<0.0001 to Veh+NC treatment. 
 
2. 6. Discussion 
The aim of this study was to identify a novel mechanism of NDRG2 regulation in skeletal 
muscle cells with a specific focus on miRNAs. Using an in silico approach, miR-23a, -23b and 
-28 were identified and their potential interaction with mouse Ndrg2 3’UTR confirmed using 
cell-based biochemical assays. Individual or combined miRNA overexpression did not inhibit 
endogenous NDRG2 under basal conditions. However, the combined overexpression of the 
miRNAs did inhibit the induction of NDRG2 protein expression following dexamethasone 
treatment. These results demonstrate a novel interplay between miRNAs and the regulation of 
NDRG2 under catabolic conditions in myotubes. 
The importance of miRNAs in skeletal muscle development and homeostasis is highlighted in 
mice expressing a skeletal muscle-specific deletion of Dicer, an endonuclease required for 
miRNA processing. Mice unable to process miRNAs within skeletal muscle develop muscle 
hypoplasia, reduced muscle mass and perinatal death (273). MiRNAs are also implicated in the 
control of muscle regeneration, dystrophies, myopathies, and in the development of 
cardiovascular and neurodegenerative diseases (reviewed in (265, 271)). How miRNAs 
function in muscle tissues is complex as they are reported to potentially ‘buffer’ against 
physiological and pathological changes to maintain homeostasis. To do this, they may target 
multiple gene transcripts in the same pathway to ensure a biological outcome, or display 
cooperativity and redundancy by synergistically targeting the same transcript (265, 271). The 
latter scenario may be the case in our study where the overexpression of miR-23a, -23b or -28 
caused the endogenous downregulation of the other miRNAs that suggests a level of 
redundancy and cooperativity in their regulation and function. Furthermore, the combined 
overexpression of the three miRNAs in the presence of dexamethasone prevented the increase 
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in NDRG2 translation. This outcome may be a reflection of the modulatory regulation of 
NDRG2 in stress scenarios but also emphasises the roles miRNAs play in disease and stress 
conditions experienced in skeletal muscle tissue. For example, miR-206-deficient mice display 
normal neuromuscular junction (NMJ) formation in healthy skeletal muscle although following 
the introduction of stress such as an acute injury causing muscle regeneration, new NMJ 
formation was impaired  (274). Furthermore, miR-206’s deficiency exacerbated disease 
progression in a mouse model of motor neurone disease (274). Whether all three miRNAs are 
required to act cooperatively or independently to inhibit NDRG2 increase during 
dexamethasone or other catabolic stress are yet unknown. However, since the effect of 
dexamethasone on NDRG2 levels is moderate, it is unlikely that individually, miR-23a, -23b 
or -28 will have a substantial effect on NDRG2 regulation. The potential co-regulation of 
NDRG2 by multiple miRNAs in skeletal muscle is further supported by a similar scenario 
reported recently in the lumbar region of embryonic sheep where target genes, including 
NDRG2, are believed co-regulated by multiple miRNAs (275). 
Each miRNA predicted to inhibit Ndrg2 in this study plays roles in skeletal muscle biological 
processes. MiR-23a, -23b and -28 are linked to myogenesis and differentiation (212, 276-278) 
with miR-23a also associated with muscle wasting (213, 279, 280). Previously, miR-23a was 
reported to decrease with dexamethasone in C2C12 myotubes at 48 h post treatment (213), and 
in miR-23a transgenic mice, miR-23a reduced dexamethasone-induced muscle wasting 
potentially through the translational inhibition of the ubiquitin proteasomal E3 ligases, 
MAFbx/atrogin-1 and MuRF1 (214). Currently, these two studies do not delineate a clear role 
for miR-23a in dexamethasone induced-stress as its downregulation is counter-intuitive to a 
function involving MAFbx and MuRF1 inhibition. Here, this observed the downregulation of 
miR-23a and of miR-23b by dexamethasone, albeit at 24 h, not at 48 h post treatment. Previous 
studies have demonstrated that dexamethasone treatment increases Ndrg2 transcription in 
murine skeletal muscle cells (176) and in rat astrocytes (272, 281) with the induction of Ndrg2 
by dexamethasone occurring indirectly through nuclear factor-κB or paired box gene 5 
transcription factor binding (272). Given our findings here, it is tempting to speculate that the 
decrease in miR-23a and -23b endogenous levels by dexamethasone may reduce their potential 
inhibition of Ndrg2 translation during Ndrg2’s stress response increase to dexamethasone. 
Regardless, these findings suggest a novel regulatory mechanism of NDRG2 translation by 
miRNAs during stress conditions. Furthermore, it appears that these miRNAs function through 
their binding to the 3’UTR of Ndrg2, rather than degradation of Ndrg2 transcripts, two known 
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mechanisms by which miRNAs can function to control gene and protein expression (reviewed 
in (45)).   
While miR-23a and -23b have not been described elsewhere to target human or rodent Ndrg2, 
miR-28-5p was reported recently to target and suppress human NDRG2 in chronic lymphocytic 
leukemia cells (46). This miRNA regulation was proposed as a mechanism to help suppress 
NDRG2 expression in cancer cells along with epigenetic silencing. This study used in silico 
and similar in vitro validation approaches involving dual luciferase assays in HEK293T where 
the authors identified miR-28 to bind to a predicted target sequence in the 3’UTR region of 
human NDRG2 (46), which helps validate our findings reported here of mouse Ndrg2 
regulation by miR-28-5p. 
Here, novel co-regulation of mouse Ndrg2 by miRNAs under specific stress conditions in 
skeletal muscle cells is described. However, the in vitro overexpression of the miRNAs in the 
presence of dexamethasone represents non-physiological conditions for the regulation of 
Ndrg2. Whether miR-23a, -23b and -28 act cooperatively under similar stress conditions in 
vivo, and whether Ndrg2 represents a novel therapeutic target in catabolic muscle wasting 





























3. 0. Effect of NDRG2 overexpression in postnatal skeletal muscle 
development using comparative viral gene therapy approaches 
 
3. 1. Abstract 
Postnatal muscle growth and development occurs primarily through hypertrophy; expansion of 
pre-existing fibres, and partly through hyperplasia; the proliferation of new muscle cells. 
NDRG2 contributes to the control of muscle cell proliferation in vitro. The primary aim of this 
study was to compare two viruses, an adeno-associated virus (AAV) and a lentivirus (LTV) to 
drive NDRG2 overexpression specifically in neonatal muscle. For this, custom-made AAV and 
LTV viruses containing muscle-specific promoters, α-actin and desmin, respectively, were 
generated to drive mouse NDRG2 expression in maturing muscle fibres and muscle satellite 
cells. A secondary aim was to investigate whether striated muscle-specific NDRG2 
overexpression could promote or alter postnatal growth through hyperplasia or hypertrophy. 
Given the small number of neonates available, an initial pilot study was performed whereby 
three-day old C57BL/6 mouse neonates were injected intraperitoneally with a LTV-mNDRG2. 
Four weeks post injection, no overexpression of Ndrg2 mRNA or NDRG2 protein was detected 
in the quadriceps or diaphragm muscles. To test whether the muscle-specific AAV or LTV 
viruses were overexpressing NDRG2, further testing was undertaken in vivo and in vitro. Each 
virus was injected intramuscularly into the tibialis anterior (TA) muscle and compared to a TA 
muscle injected with an AAV containing a high-expressing cytomegalovirus (CMV) promoter 
driving the overexpression of human NDRG2. Overexpression of human NDRG2 transcripts 
and NDRG2 protein was obtained with the AAV1-CMV virus but little if any increase in 
mRNA or protein expression for mouse NDRG2 was measured with -actin and desmin driven 
AAV1 and LTV. Furthermore, the transduction of C2C12 myoblasts with different 
concentrations of the viruses resulted in a 2-4.5-fold increase in Ndrg2 mRNA expression with 
the highest dose tested for either muscle-specific virus. No increase in NDRG2 protein levels 
was measured in C2C12 myoblasts or myotubes. These findings indicate that the muscle-
specific AAV and LTV viruses designed to overexpress NDRG2 specifically in muscle cells 
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were unable to do so efficiently. Therefore, the hypothesis that NDRG2 could promote or alter 
postnatal growth through hyperplasia or hypertrophy could not be determined. 
 
3. 2. Introduction 
Postnatal muscle growth in mice occurs through hypertrophy and hyperplasia of muscle fibres, 
as well as the completion of postnatal progenitor cell division during the first 3-4 weeks after 
birth (15). Normal muscle development during early postnatal life is critical and abnormal 
changes to the normal developmental process can permanently impact skeletal muscle growth, 
contractile function and metabolic maturation (34-38). This highlights the importance of 
normal postnatal growth and therefore understanding the molecular mechanism that may 
influence this process is of fundamental importance. NDRG2 expression is increased during 
myoblast differentiation in both mouse and human cells (176) and during mouse embryonic 
development (166). Its suppression reduced skeletal myoblast proliferation (176), while in 
contrast its overexpression increased myoblast proliferation (179). Combined, these data 
support the role of NDRG2 as a regulator of myogenesis, at least in vitro. Whether increased 
levels of NDRG2 can enhance proliferation and muscle growth postnatally is yet to be 
determined. A challenge to establish the potential of NDRG2 to influence postnatal growth is 
the development of tools that can overexpress NDRG2 specifically in striated myoblasts and 
progenitor cells in vivo. 
Tissue-specific regulation of genes of interest in postnatal animal models can be achieved via 
the use of adeno-associated viruses (AAVs) and lentiviruses (LTVs). AAV and LTV viral 
delivery approaches have been used to study postnatal muscle development, using muscle 
specific promoters (225, 249, 254, 282-285).  The utility of these viruses has advantages and 
disadvantages over one another. AAVs are among the most widely and regularly used viral 
vectors for transduction in post-mitotic cells, including skeletal muscle (reviewed in (286)).  In 
vitro, AAVs transduce myotubes more efficiently than myoblasts, while muscle satellite cells 
are refractory to AAV6 transduction (248). In pre-clinical applications, AAV-derived 
transgene expression is sustainable, safe and consistent over time (287). Recently, different 
AAV serotypes with variable tropism were developed for efficient transduction (288). 
Although many of the serotypes have the ability to transduce skeletal muscle (289, 290), AAV1, 
AAV6 and AAV9 are the serotypes regularly used in pre-clinical studies to transduce skeletal 
muscle (287) as these serotypes do not elicit a strong immune response (223, 227). In contrast 
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to AAVs, LTVs infect both dividing and non-dividing cells, including muscle satellite cells 
(250, 251, 254). However, LTVs can induce immune responses following transduction (291).  
Tissue-specific transduction and hence transgene expression is influenced by not only the type 
of virus and dose used but also by the promoter that drives the transgene (292-295). Common 
promoters used for whole body overexpression of striated muscle include desmin (254, 296, 
297), a muscle cytoskeletal protein that belongs to an intermediate protein filament family (298, 
299), and α-actin (282, 300), a major component of the thin filament in skeletal muscle (301). 
Therefore, the initial aim of this study was to use two viral approaches to overexpress mouse 
NDRG2 specifically in the striated muscle of mouse neonates in vitro and in vivo using AAV1 
and LTV under the control of the alpha-actin and desmin promoters, respectively. The 
overexpression of human NDRG2 by AAV1 under the control of the ubiquitous CMV promoter 
was used as a positive control, as this has been established to efficiently overexpress NDRG2 
following an intramuscular injection. If successful, the effect of muscle-specific NDRG2 
overexpression on postnatal muscle development would be measured.  
 
3. 3. Materials and methods 
3. 3. 1. Virus production and delivery 
The construction and production of AAV1-α-actin-mN (AAV1-α-actin expressing mouse 
NDRG2), AAV1-CMV-hN (AAV1-CMV expressing human NDRG2) and empty control 
viruses (AAV1-α-actin-Con and AAV1-CMV-Con) were performed by Vector Biolabs 
(Malvern, PA, USA). Stock titres for each virus ranged from 1-5 x 1013 vector genomes (vg) 
per millilitre which were diluted to 5x1011 vg/ml each for use as working stocks. The muscle 
specificity of NDRG2 overexpression is controlled through a 1.5 kb fragment of the human α-
actin gene promoter, containing important proximal and distal regions, that can drive the 
expression of genes in neonatal striated muscle within 15 days post injection as described 
previously (282). The CMV permits high ubiquitous expression in a broad range of cell and 
tissue types (292, 302, 303). For the LTVs, based on other published studies (254), muscle-
specific LTVs using 1.2 kb of the desmin promoter were generated to overexpress mouse 
NDRG2 or control empty vector. In addition, ZsGreen, a green fluorescent protein derived 
from reef coral (304), was included downstream of an internal ribosomal entry site (IRES) to 
help monitor transgene expression. ZsGreen was expressed separately to NDRG2 due to the 
54 
 
presence of the IRES sequence, and not conjugated. The viruses and their vectors, LTV-
desmin-mNDRG2-IRES-ZsGreen (LTV-Des-mN) and LTV-desmin-IRES-ZsGreen (LTV-
Des-Con), were synthesised and produced by Creative Biogene (Shirley, NY USA) with a stock 




Figure 3. 1. Vector maps for AAV1 and LTV used to overexpress mouse NDRG2 in 
neonatal mouse muscle.  
 
3. 3. 2. Mice and viral dosing 
C57BL/6 pregnant dams were obtained from the Animal Resource Centre (ARC, Canning Vale, 
WA). Mice were housed at room temperature of 21 ± 2 oC, humidity between 40-70% with a 
12-hour light/dark cycle and allowed to give birth in accordance with Deakin University animal 
ethics committee (ethics project code: G36-2014). To investigate the systemic delivery of the 
LTV, three-day old neonate C57BL/6 mice were injected intraperitoneally (i.p.) with LTV-
Des-mN or LTV-Des-Con using 30G insulin syringe (BD Ultra-FineTM II). A maximal LTV 
dose of 2x106 TU was injected in a 20 l volume per animal (<1% body weight) as permitted 
by Deakin University Ethics Committee. Animals were humanely sacrificed 4 weeks post-
injection (completion of postnatal progenitor cell division) and muscle (TA, quadriceps, 
gastrocnemius, heart and diaphragm) and non-muscle (liver, kidney and lung) tissues were 
collected for analysis. N=3 per treatment groups were performed as a pilot study. 
 
To investigate the expression of the AAV1 and LTV viruses intramuscularly, 1-2 mice received 
direct injections into the TA muscle of each virus diluted in 30 l saline. Based on prior work 
to obtain significant NDRG2 overexpression through AAVs (Anderson and Foletta, 
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unpublished observations), a dose of 5x1011 vg was injected for each AAV1 virus (AAV1-α-
actin-mN or AAV1-CMV-hN), and a maximal dose of 3x106 TU of LTV-Des-mNDRG2) was 
injected in 30 l volumes. The contralateral TA muscles were injected with the respective 
control viruses. Animals were humanely sacrificed 4 weeks post-injection and TA muscles 
were collected for analysis. 
 
3. 3. 3. Cell culture 
Mouse C2C12 myoblasts (ATCC, Manassas, VA, USA) were cultured in growth medium at 
37°C in 5% CO2. To differentiate cells, a medium consisting of 2% horse serum and 25 mM 
glucose DMEM medium was added when cells were confluent and refreshed every 48 h over 
a 6-day period. For the C2C12 myoblast and myotube infections, LTV-Des-mN (1x108 TU/ml 
stock) were diluted 1:20 (final concentration, 5x106 TU/ml), 1:80 (final concentration, 1.25x106 
TU/ml) or 1:320 (final concentration, 3.13x105 TU/ml) in DMEM medium. The AAV1-α-
actin-mN virus (5x1011 vg/ml starting stock) was diluted to 1:20 (final concentration, 2.5x1010 
vg/ml) and 1:200 (final concentration, 2.5x109 vg/ml). Viral infection was performed as 
described previously (249, 305-308), which involved 45 min centrifugation at 1800 rpm and 
virus incubation of 4 h at 37oC in 5% CO2 before media change. Cells were harvested 72 h post 
transduction. 
 
3. 3. 4. Total RNA extraction  
For total RNA extraction from tissues, approximately ~10 mg of tissue was homogenised in a 
tube containing zirconia/silica beads and 500 μl of TRI-reagent solution (Ambion®) using a 
MagNALyser (Roche Life Science; Mannheim, Germany). For RNA extracted from cultured 
cells, cells were collected in 400 l TRI-reagent solution. RNA extractions were performed 
according to the manufacturer’s instructions. Briefly, following homogenisation, 60 μl of 1-
bromo-3-chloropropane (Sigma) were mixed into the samples and left at room temperature for 
5 minutes to allow for phase separation before centrifugation at 14,000 rpm. The clear upper 
phase was collected followed by isopropanol addition; and then RNA was allowed to 
precipitate for one hour in case of cells and overnight at -20ºC for tissues. After 60 min or 24 
h incubation at -20oC, the RNA was pelleted and resuspended in nuclease free water (NFW) 
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after washing in 75% ethanol. RNA concentration and purity were assessed with the NanoDrop 
2000 spectrophotometer (NanoDrop products, Wilmington, DE). 
3. 3. 5. Semi-quantitative Polymerase Chain Reaction  
Gene expression levels were measured by semi-quantitative PCR (qPCR). Briefly, 1 μg RNA 
was reverse transcribed to cDNA using Oligo-dT primers from a High Capacity RNA-to-cDNA 
kit (Applied Biosystems). Each 20 μl qPCR reaction contained 5 ng/μl cDNA, 0.5x Power 
SYBR green PCR master mix (Applied Biosystems) and the gene of interest forward and 
reverse primers (2µM) on a Stratagene Mx3000 PCR machine (Stratagene, La Jolla, CA, USA). 
The qPCR cycling conditions were: 95°C for 10 min (1 cycle), 30 s at 95°C and 60°C for one 
min (40 cycles). To show that only one product has been amplified during each PCR, a 
dissociation curve was generated for each primer set. Samples were measured in duplicate gene 
expression levels were calculated using the 2−ΔCt formula following normalization to 36B4 
cycle threshold (Ct) levels. Primer sequences for human and mouse NDRG2, 36B4 and 
ZsGreen genes are listed in Table 3.1 
 




Forward (5’ – 3’) Reverse (5’ – 3’) 
hNDRG2 GGAGACACCATACGGCTCT CGGGTGGTTAAGAGCATATC 




ZsGreen GGCTCAGTCAAGCACGGT CCACCTTCGACCACACACA 
36B4 GCTGCCTCACATCCGGG  AGCTGGCACCTTATTGGCC  
 
3. 3. 6. Western Blotting 
Twenty micrograms of each protein sample were analysed using a standard western blotting 
method. Samples were electrophoresed in a running buffer (25 mM Tris-base, 200 mM glycine, 
0.1% sodium dodecyl sulphate (SDS)) on a gradient (4-20%) SDS-PAGE gel at 180 V using a 
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Mini-PROTEAN 3 cell apparatus (Bio-Rad). Proteins were transferred to a 0.45 μm low 
fluorescence membrane (Merck Millipore) using the Mini Trans-Blot electrophoretic transfer 
cell (Bio-Rad) with chilled transfer buffer (25 mM Tris-base, 192 mM glycine, 10% methanol) 
at 100 V for 1 hour. Membranes were blocked in 5% BSA and Tris-buffered saline (TBS; 40 
mM Tris, 273 mM sodium chloride) and incubated in the primary antibody overnight at 4ºC 
with gentle rocking. Membranes were washed with TBS and 0.1% Tween-20 (Astral Scientific) 
(TBST) and probed with the secondary antibodies, goat anti-rabbit AlexaFluor®680 or donkey 
anti-mouse AlexaFluor®800 IgG antibodies (Life Technologies) diluted at 1:10,000 in 50% 
TBS, 50% Odyssey Blocking Buffer (Li-COR Biosciences, Lincoln, NE, USA) and 0.01% 
SDS. Membranes were scanned on the ODYSSEY® Infrared Imaging System (Millennium 
science). Densitometry analysis was performed using Image Studio Lite software, ver.5 (Li-
COR Biosciences). Protein levels were normalized to GAPDH expression levels. The 
following primary antibodies were used: rabbit polyclonal anti-NDRG2 antibodies 
(HPA002896; 1:5000, Sigma–Aldrich), mouse monoclonal ZsGreen antibody (# 632598, 
1:1000, Takara: Living Colors®) and mouse monoclonal anti-GAPDH antibody (G8795, 
1:1000, Sigma-Aldrich, Castle Hill, NSW). 
 
3. 4. Results 
 
3. 4. 1. Lentivirus treatment of mouse neonates and NDRG2 overexpression 
investigation 
 
To determine whether the LTV-Des-mN virus successfully overexpressed mouse NDRG2 in 
postnatal mouse muscles, a pilot study was performed. The mRNA and protein expression 
levels of NDRG2 were measured in the quadriceps muscle. Only NDRG2 protein expression 
was measured in the diaphragm due to insufficient tissue to extract both protein and RNA. No 
increase in mouse NDRG2 levels of mRNA (Figure 3.2A) or protein in either the quadriceps 
(Figure 3.2B) or in the diaphragm (Figure 3.2C), was observed when compared with LTV-Des-
Con. Therefore, further tissue analysis of NDRG2 expression in the neonate tissues was halted 





Figure 3. 2. NDRG2 mRNA expression in quadriceps of neonates following systemic 
lentivirus transduction. C57BL/6 neonates were injected intraperitoneally with LTV-Desmin-
IRES-ZsGreen (C; LTV-Des-Con) or LTV-Desmin-mNDRG2-IRES-ZsGreen (N; LTV-Des-
mN). Ndrg2 mRNA (A) and NDRG2 protein levels (B) in quadriceps (Quad), and NDRG2 
protein expression in the diaphragm (C) are represented. The data represents an average of 
n=3 mice per group. 
 
3. 4. 2. Transduction of AAVs and LTVs in vitro  
Next, different concentrations of the muscle-specific AAVs and LTVs to determine if these 
viruses are able to overexpress mouse NDRG2 in vitro in myoblasts and myotubes were tested. 
The highest AAV--actin-mN concentrations used caused a 2-fold increase in Ndrg2 mRNA 
in myoblasts (Figure 3.3A) and a 1.5-fold increase in myotubes (Figure 3.3B). The highest 
concentration of LTV used caused a 4.5-fold and 10-fold increase in Ndrg2 mRNA (Figure 
3.3A) and ZsGreen mRNA (Figure 3.3C), respectively, compared to the transduced empty 
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vector in myoblasts. However, no detectable overexpression of either NDRG2 (Figure 3.3B) 
or the ZsGreen tag (Figure 3.3D) proteins was observed in the transduced myoblast and 
myotubes (Figure 3.3E-F). This experiment was performed with sample numbers of n=1-2, 





Figure 3. 3. NDRG2 and ZsGreen mRNA and protein expression in LTV & AAV transduced C2C12 myoblasts and myotubes. C2C12 
myoblasts and myotubes were transduced with a range of LTV and AAV1 doses. Stock LTV-Des-mN (LTV; 1x108 TU/ml) was diluted 1:20
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, 1:80 and 1:320. Stock AAV1- Actin-mN (AAV1; 5x1011 vg/ml stock) was diluted 1:20 and 
1:200. Ndrg2 mRNA levels in myoblasts (A) and myotubes (B), and ZsGreen mRNA levels in 
myoblasts (C) and myotubes (D). NDRG2 protein levels in LTV–transduced myoblasts and 
myotubes (E) following normalization to GAPDH expression levels. Data represents n=1 per 
treatment condition. 
 
3. 4. 3. Intramuscular injection of LTVs and AAVs into TA muscles  
Next, a small comparative pilot study was performed by injecting intramuscularly (i.m.) the 
muscle-specific LTVs, muscle-specific AAVs or an AAV1 overexpressing hNDRG2 under a 
CMV promoter in an attempt to drive NDRG2 overexpression in TA muscle. AAV1-CMV-hN 
has shown successful overexpression of human NDRG2 following 4 weeks post i.m. injection 
in our research group previously (Anderson and Foletta, unpublished findings). The analysis 
of Ndrg2 mRNA in the TA muscles indicated that mouse Ndrg2 mRNA levels were slightly 
higher (1.4-fold) in LTV-Des-mN injected (Figure 3.4A) or unchanged in AAV1-α-actin-mN 
(Figure 3.4B) compared to the control viruses injected into the contralateral TA muscles. 
However, clear induction of human NDRG2 mRNA levels was evident in the AAV1-CMV-hN 
injected muscles compared to the AAV1-CMV-Con where negligible human NDRG2 gene 
expression was detected (Figure 3.4C). There was no evidence of increased mouse NDRG2 
protein levels above endogenous NDRG2 levels in TA muscles injected with muscle-specific 
LTV or AAV1 viruses whereas overexpression of human NDRG2 protein from the AAV1-
CMV virus was observed in addition to endogenous NDRG2 levels (Figure 3.4D and 3.4E). 
To note, this comparative experiment is a small pilot study with insufficient samples present 
for statistical analyses. 
 
 




Figure 3. 4. Mouse and human NDRG2 mRNA and protein expression in TA muscles following LTV and AAV intramuscular injections. Mouse 
NDRG2 mRNA (A) and protein (D) expression in LTV-transduced TA muscles (n=1). NDRG2 mRNA (B) and protein expression in AAV1-α 
Actin (D and E) or AAV1-CMV (C, D and E) transduced TA muscles (n=2 per group). Human Ndrg2 mRNA expression in AAV1-CMV 




3. 5. Discussion  
This pilot study aimed to identify an efficient viral technique to deliver and overexpress mouse 
NDRG2 specifically in mouse striated muscles during early postnatal growth. Lentiviral and 
AAV approaches were used to target muscle satellite cells, myoblasts and more mature 
myofibres. NDRG2 overexpression was not attained following transduction with a maximal 
dose available of LTV with the modified desmin promoter when injected systemically or 
intramuscularly.  Furthermore, NDRG2 overexpression was not achieved using an AAV1 α-
actin-derived promoter upon intramuscular injection whereas AAV1 with a CMV promoter did 
result in human NDRG2 overexpression. Despite testing a range of doses of both AAVs and 
LTVs designed to overexpress NDRG2 in myoblasts and myotubes in vitro, efficient 
exogenous expression of NDRG2 was not obtained. 
The transduction efficiency and hence transgene expression primarily depends on promoter 
region and type, AAV serotypes (reviewed in (309)), dose (292-295, 310), transgene 
expression cassette and capsid (294, 311, 312). For example, the addition of 1.5 kb DNA 
fragment containing α-actin enhancer promoter and part of the first intron to AAV8 caused 
enhanced transgene expression (282). Moreover, transcription in skeletal muscle cells was 
induced 10-fold using the distal promoter of skeletal muscle α-actin (−1282 to −708), and if 
used in conjunction with the proximal promoter (−153 to −87), a 100-fold increase was 
achieved (313). However, transcription is decreased 10-fold if a deletion within the distal 
regulatory element (Δ −1282/−1151) is present in the 2000 bp full length α-actin promoter 
suggesting the importance of specific regions of promoters required for driving gene expression 
(314). This, however, was not reproducible in our study despite using a 1.5kb promoter region 
containing fragments from both distal and proximal regions. 
The expression of a transgene may be regulated by the type of promoter used as well. In cardiac 
and skeletal muscle tissues, five different promoters including CMV, desmin, alpha-myosin 
heavy chain, myosin light chain 2 and cardiac troponin C using rAAV2/9 serotypes have been 
tested for broad biodistribution of expression in BALB/c neonatal mice (315). The LacZ 
expression revealed that the desmin promoter (354 bp) was highly effective for expression of 
the transgene in skeletal and cardiac muscle while an alpha-myosin heavy chain promoter 
increased focal expression in cardiac tissue only (315). These studies suggest that transgene 
expression efficacy is modulated by the type of promoter used. Likewise, another study 
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compared CMV and muscle creatine kinase (MCK) promoter and confirmed that MCK 
promoter drove higher and more sustained transgene expression than the CMV promoter (316).  
AAV serotype is also linked to tropism and biodistribution of the virus in different organs 
depending on the mode of injection (288, 317). AAV8 is more efficient than AAV9 in 
transducing muscles of neonatal puppies (318). Furthermore, in both neonates and adults, 
AAV8 has been demonstrated to show maximum efficacy in striated muscles throughout the 
body upon systemic delivery while AAV1 and AAV6 were efficiently transduced in local 
muscle following intramuscular delivery (255). This demonstrates AAV transduction 
efficiency is modulated by the mode of delivery. Further, the mode of delivery of the same 
serotype also alters transgene expression, For example, when injected intravenously or 
systemically, AAV5-driven human coagulation factor IX transgene expression was greater 
following systemic administration (319).   Together, these studies suggest that using AAV8 
serotype, rather than AAV1, with an optimal promoter region may be required to induce 
systemic overexpression of genes in neonatal muscles.  
Given that NDRG2 overexpression was achieved using AAV1-CMV-hNDRG2, one could 
potentially argue that this virus can induce overexpression in neonates. However, the muscle-
specific expression may not be achieved. Moreover, injecting a CMV-driven adenovirus in 
neonates demonstrated that the CMV promoter is not particularly active in neonatal rat cardiac 
muscle tissue under basal conditions (307). Similarly, CMV promoter inactivation after gene 
transfer has been shown in vivo in mouse liver (320) as well as in smooth muscle cells (321) 
and primary cardiac fibroblasts (322). Although short-term high expression is achieved, the 
CMV driven transgene expression becomes silent within a few weeks (323, 324). Here, the 
CMV promoter activity peaked at 2 to 4 days post delivery and declined within 4 weeks to 
scarcely detectable levels (323-325). Hence, these studies suggest that using CMV promoters 
in neonates may not be the best way to increase NDRG2 levels in muscles. However, this study 
and previous findings from our lab (Anderson and Foletta, unpublished findings) demonstrate 
that CMV driven AAV1 can overexpress NDRG2 in adult mouse muscle upon intramuscular 
injection. Therefore, this approach has been used in chapters 4 and 5 to achieve mouse NDRG2 
overexpression and investigate overexpression effects in adult mouse muscle under basal and 
catabolic conditions.     
During the transduction in the neonatal mouse as well as in C2C12 myoblasts and myotubes, 
LTVs with a desmin promoter have been demonstrated to increase transgene expression six- to 
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eight-fold greater per viral copy than the muscle-specific human MCK promoter (254). In this 
same study, one day old mice were injected with 2x106 and 2x107 TU through intravascular 
injection close to TA muscle and muscles analyzed post 8 weeks or at higher times. The LTV 
concentration used here was based on published studies (254) but limited by the LTV 
concentration and volume of the stock provided by Creative Biogene at 1 x 108 TU/ml as well 
as by ethical dosing of the neonates permitted by Deakin University Ethics Committee. 
Intramuscular injection of 1 x 108 TU/ml directly into neonatal TA muscle resulted in stable 
and increased dystrophin gene expression (253). Although the virus dose injected in our study 
was comparable to others (254), NDRG2 overexpression was not achieved. NDRG2 is highly 
expressed in skeletal muscle tissues (326) and potentially no overexpression could be detected 
due to the presence of strong endogenous NDRG2 levels indicating higher doses may be 
needed. Interestingly, the highest dose of LTV in our study appeared to induce a 10-fold 
increase in NDRG2 expression in myoblasts compared to the empty vector suggesting that 
higher doses may generate successful overexpression. However, cost and time limitations did 
not permit the development of higher LTV stock titres.  
In summary, although AAVs and LTVs were designed with muscle-specific promoters to 
overexpress NDRG2 specifically in neonatal muscles and muscle cells, these were unable to 








































    
4. 0. Characterising the effect of NDRG2 overexpression on skeletal 
muscle in the fed and fasted states   
 
 
4. 1. Abstract 
NDRG2 is a stress response gene that may contribute to the control of muscle mass. This study 
investigated whether sustained, elevated NDRG2 levels altered skeletal muscle mass and stress 
signalling pathways linked to muscle protein translation under basal and fasting conditions.  
NDRG2 was overexpressed in the right tibialis anterior (TA) muscle following adeno-
associated virus serotype 1 (AAV1) injection. The contralateral TA muscle was injected with 
a control AAV1. Four and eight weeks post injection, mice were fasted for 24 hours or 
remained fed, followed by collection of the TA muscles. AAV1-NDRG2 overexpression was 
observed at both 4 and 8 weeks post injection. Decreased TA muscle mass in the NDRG2-
treated muscles was observed at both time-points.  Fasting reduced body weight and plasma 
glucose levels, but had no effect on TA muscle weight, cross sectional area or fibre type. 
Markers of protein degradation (MuRF1 and atrogin-1) and autophagy (LC3), as well as 
endogenous NDRG2 expression and calpain activity, increased with 24 h fasting. The E3 ligase 
Trim32 mRNA and the apoptotic marker caspase 3 remained unchanged following fasting or 
following NDRG2 overexpression. Furthermore, there was no change in the phosphorylation 
or total protein levels of p38-MAPK and AMPKα or in the protein translation initiation proteins 
measured.  Calpain activity increased slightly in fasted muscle overexpressing NDRG2. These 
findings indicate that although a marginal decrease in muscle mass was observed with NDRG2 







4. 2. Introduction 
 
Muscle atrophy is a physiological response to prolonged fasting. During fasting decreased 
muscle mass may occur due to activation of ubiquitin-proteasome (120), increased autophagy 
and protein synthesis pathway suppression (327, 328), dysregulation of calpains (calcium 
dependent proteases) (68) and activation of nutrient sensitive adenosine monophosphate-
activated protein kinase (AMPK) pathway (327). The imbalance in protein turnover, resulting 
in a net loss of muscle protein, especially contractile proteins, occurs when protein synthesis is 
reduced and protein degradation is increased (115). The reduction in protein synthesis is due 
to reduced rates of translation (116), translation initiation (117) and ribosomal content in the 
cell (118). The formation of initiation complex requires eukaryotic translation initiation factor 
4E (eIF4E) which is inhibited by phosphorylation of inhibitory eIF4E binding protein, 4EBP1. 
The transcriptional profiling of rodent gastrocnemius muscles revealed mRNA levels of the 
eIF4E remain constant while 4EBP1 increases in 24h fasted (328). On the other hand, 
upregulated degradation of muscle proteins may occur due to the following pathways during 
nutrient deprivation. During fasting, the increased breakdown of muscle proteins, primarily 
due to the activation of the ubiquitin-proteasome pathway following activation of the E3 ligases 
MuRF1 and atrogin-1 (329), provides amino acids needed for oxidation in the muscle (330). 
In addition, myofibrillar proteins may be degraded by calpain proteases which are activated 
during fasting (68, 123). Autophagy is another process activated during fasting and involves 
cell component turn over during normal and various stress conditions including nutrient 
deprivation (331). In fasting muscle, autophagosome formation rate is maximum with higher 
content in fast glycolytic muscles than slow oxidative muscles (78, 81). LC3, a protein that 
contributes to autophagosome formation, increases in rodent muscles when fasted for more 
than 10 hours (78, 79, 82, 83). Moreover, AMPK regulates autophagy and responds to energy 
and nutrient stress to maintain energy balance through phosphorylation of diverse metabolic 
pathways (83, 332). Activation of AMPK pathway may further activate mitogen-activated 
protein kinase (MAPK) signalling. The p38 MAPK regulates muscle development through 
activation of transcription factors which modulate protein synthesis (333). In addition, it also 
regulates the phosphorylation of eIF4E (334). Although multiple studies have targeted specific 
mechanisms involved, understanding of how different pathways function together to cause 
muscle mass loss during fasting is incomplete. In addition, identifying novel regulators of 
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muscle mass under basal and stress situations will help further our understanding of the 
molecular mechanisms controlling muscle catabolism.   
The N-myc downstream-regulated gene 2 (NDRG2) gene is a stress-response gene linked to 
myogenesis (176) and protein turnover in skeletal muscle cells (177). Its expression is reduced 
in response to resistance exercise training, a hypertrophy causing signal, whereas its expression 
is induced following an acute bout of endurance exercise in humans (176). It is upregulated in 
C2C12 myotubes treated with dexamethasone, a catabolic agent causing atrophy, and 
downregulated in more growth promoting, anabolic conditions (176). NDRG2 overexpression 
in C2C12 myotubes results in decreased protein synthesis and, MHC2b and MHC2x mRNA, 
potentially via, MAPK signalling (177). These results suggest that in response to catabolic or 
anabolic stress NDRG2 could regulate muscle mass via controlling protein synthesis pathways, 
with a paralleled change in muscle fibre type. Whether it does so in vivo under basal or stressed 
conditions is yet to be explored. 
The aim of this study was to determine if NDRG2 overexpression altered muscle mass and/or 
stress response pathways in skeletal muscle under basal and fasting conditions. Using adeno-
associated virus 1 (AAV) serotype, NDRG2 was overexpressed in the right tibialis anterior 
muscle of mice with a control AAV virus injected into the left TA. Four or eight weeks post 
injection, to allow for stable NDRG2 expression and potential changes to muscle fibre-type, 
mice were fasted for 24 h or remained fed prior to humanely killing and collection of blood 
and TA muscles. The impact of increased NDRG2 levels on different protein degradation and 
nutrient-stress sensitive pathways was analyzed.      
    
4. 3. Materials and methods 
 
4. 3. 1. Intramuscular injections of AAV1-mNDRG2 and AAV1-null control 
viruses 
 
Twelve week old male C57BL/6 mice were obtained from the Animal Resource Centre 
(Canning Vale, WA). Mice were housed at room temperature of 21 ± 2oC, humidity between 
40-70% with a 12-hour light/dark cycle in accordance with the Deakin University animal ethics 
committee (ethics project code: G07-2017). 1x1010 viral genomes of AAV1 encoding mouse 
NDRG2 (AAV1-NDRG2) or an AAV1-null control virus, diluted in 30 µl of 0.9% sodium 
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chloride, were injected intramuscularly into the right tibialis anterior (TA) and left TA, 
respectively. Four and eight weeks post injection, mice were weighed, baseline serum collected 
and fasted for 24 hours or remained fed. Following fasting, mice were weighed and then 
humanely killed. Blood serum was collected and TA tissues were harvested, weighed and snap 
frozen in liquid nitrogen-chilled isopentane and stored at -80oC. The time point of 24 h for 
fasting was chosen due to ethical approval concerns raised by Deakin University Animal Ethics 
Committee. Longer duration was considered too harsh for the animals. Moreover, 24 h fasting 
was chosen because the study aimed to investigate the effects of NDRG2 overexpression at 
molecular level which are activated soon after fasting is initiated. 
 
4. 3. 2. Tissue Preparation 
AAV1-NDRG2 and AAV1-null infected TA muscles were cut transversely at the mid-belly 
with a scalpel blade. For protein and RNA analyses, the proximal portion was freeze-dried 
(Modulyo® Freeze Dryers, #F05630000, Thermo Electron Corporations), powdered and stored 
at -80oC. The distal portion with the tendon was used for sectioning. Samples were mounted 
using Tissue Tek® O.C.T™ (Sakura, AJ, NLD) and cryosectioned into 8µm transverse 
sections in the Leica CM1850 Cryostat at -20oC (Leica Biosystems, VIC, AUS) followed by 
mounting on silane-coated Star Frost glass slides (Medline scientific, OX, UK) for staining. 
Left and right TA muscle sections from the same mouse were mounted together on the same 
glass slide for analysis. Mounted sections were stored at -80oC until required. 
 
4. 3. 3 Fibre type, count and size 
Based on the previous publication from our group (335) and others (336), muscle fibre type 
was determined by staining with MHC1, MHC2a, MHC2b and Laminin antibodies. Unstained 
fibres were classified as MHC2x. Briefly, tissue sections were blocked in 10% goat serum/PBS 
at room temperature for 1 hr before incubating in a cocktail of primary antibodies 
(Developmental Studies Hybridoma Bank, University of Iowa, IO, USA) (Table 4.1) diluted 
in blocking buffer for 2 h. Samples were then washed three times in PBS for 15 min and 
incubated for 1 hr with secondary antibody (from Life Technologies) cocktail in blocking 
buffer (Table 4.1) under dark conditions. Following washing three times in PBS for 15 min, 
sections were mounted in Prolong ® Gold anti-fade reagent (Thermo Fisher) and coverslipped 
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before imaging using the Olympus FV10i confocal microscope (Olympus) at 10x and 20x 
magnification. Fibre types and total fibre number were calculated by counting every fibre in 
each field of view, >1,000 fibres per TA section using CellSens Dimension software (Olympus, 
version 1.12) while fibre size was calculated by measuring the minimal Feret’s diameter to 
represent the cross-sectional area of every whole fibre per field of view (>800 fibres per TA 
section, n = 5 per treatment as previously published (335)). 
 
Table 4. 1. Antibodies used for MHC fibre type analysis 
 
Protein 1o Ab & concentration 2o Ab & concentration 
MHC I BA-F8 (1:20) AlexaFluor® 350 IgG2b, blue (1:500) 
MHC 2a SC-71 (1:50) AlexaFluor® 488 IgG1, green (1:500) 
MHC 2b BF-F3 (1:20) AlexaFluor® 555 IgM, red (1:500) 
Laminin Sigma, rabbit IgG, stains cell 
membrane (1:100) 
AlexaFluor® 405 anti-rabbit, (1:500) 
 
4. 3. 4 Hematoxylin and eosin staining 
Muscle sections were stained with hematoxylin and eosin (H&E) to identify any structural 
changes to the fibres and for fibres displaying centrally located nuclei, which is a marker of 
muscle regeneration. H&E staining was performed based on methods previously published by 
our group (337, 338). Briefly, muscle sections were incubated in a Coplin jar containing 
Mayer’s hematoxylin solution (Sigma-Aldrich) for 4 min, washed in deionized water and then 
incubated in eosin Y solution (Sigma-Aldrich) for 4 min. Sections were then dehydrated by 
dipping into 95% and 100% ethanol followed by xylene (Sigma-Aldrich) submersion prior to 
coverslipping and mounting in DPX mounting medium (Sigma-Aldrich). Samples were 
imaged at 20x magnification using the Olympus IX70 fluorescent microscope (Olympus). 
Images were observed for any difference in central nuclei and structural changes per TA section 




4. 3. 5. Calpain activity assay 
Calpain activity in the muscle lysates was determined as described previously (339, 340) with 
slight modifications. Approximately 2 mg of the freeze-dried TA muscle powder was incubated 
overnight at 4oC in a digestion buffer (200 mM Tris-based buffer with 2 mM sodium azide and 
0.1% β-mercaptoethanol). Samples were centrifuged and BCA assay performed on supernatant 
to determine protein concertation. Protein amounts were equalized to 1 mg protein per ml and 
calpain activity was determined using 4, 4-difluoro-5, 7-dimethyl-4-bora-3a, 4a-diaza-
sindacene-3-propionic acid labelled casein (BODIPYFL-casein, Invitrogen) as a calpain 
substrate. Muscle lysate (50 μg protein) and the labelled casein were added to a black-walled 
microtitre plate and incubated under dark conditions at 25oC for 60 min. The reaction was 
stopped by adding 25 μl of 100 mM EDTA, and fluorescence was read at 485 nm excitation 
and 528 nm emission wavelengths using a Synergy 2 Multi-Mode microplate reader (BioTek, 
Winooski, VT, USA). The activity was measured as the difference between the activities 
measured in the presence of 1mM calcium and those where 100 mM EDTA was added but no 
calcium. Assays were performed 2-3 times under similar conditions. 
 
4. 3. 6. RNA extraction and qPCR 
RNA was extracted, cDNA synthesized and qPCR run as per the protocols described in 
(Chapter 3) with the difference that freeze-dried tissue powder was used instead of wet TA 
muscle and AriaMx Real-Time PCR System (Agilent Technologies) was used to run qPCR. 
The primer details are in Table 4.2. 
Table 4. 2. qPCR primers used for mRNA analysis  
 




Forward (5’ – 3’) Reverse (5’ – 3’) 
mNDRG2  NM_013864.2 300 cccacacagacctcgttcc gccatcgatggatgctgca 
36B4/Rplp0 NM_007475.5 300 ttgtgggagcagacaatgtg agtcctccttggtgaacacg 
MHC2a/Myh2 NM_001039545.2 300 gagcaaagatgcagggaaag taagggttgacggtgacaca 
MHC2b/Myh4 NM_010855.3 300 acagactaaagtgaaagcc ctctcaacagaaagatggat 





4. 3. 7. Protein extraction and western blotting 
Protein extraction from powdered TA muscle and quantification through BCA assay was done 
as per the protocols described in Chapter 3. Twenty micrograms of protein lysates were 
electrophoresed on 4–12% Criterion™ XT Bis-Tris Protein Gels, 26 well, 15 µl (#3450125, 
BIO-RAD). The details of the antibodies used are listed in table 4.3. Total protein levels in the 




Table 4. 3. Antibodies used for western blots to determine protein expression 
 
Antibody Antibody Type Dilution Catalogue No.  Company 
NDRG2 Rabbit Poly. 1:5000 #HPA002896 Sigma–Aldrich 
Caspase 3 Rabbit Poly. 1:1000 #9662S Cell Signalling 
LC3 Rabbit Poly. 1:1000 #2775 Cell Signalling 
Total-eIF4E Rabbit Poly. 1:1000 #9742 Cell Signalling 
p-eIF4E Rabbit Poly. 1:1000 #9741 Cell Signalling 
total-4EBP1 Rabbit Poly. 1:1000 #9452 Cell Signalling 
p-4EBP1 Rabbit Poly. 1:1000 #2855 Cell Signalling 
Total-p38 MAPK Rabbit Poly. 1:1000 #9212 Cell Signalling 
p-p38 MAPK Rabbit Poly. 1:1000 #9211 Cell Signalling 
Total-AMPKα Rabbit Poly. 1:1000 #2532 Cell Signalling 
p-AMPKα Rabbit Poly. 1:1000 #2531 Cell Signalling 
   
 
 
4. 4. Statistics  
All data are reported as the mean ± standard error of the mean (S.E.M.). The number of 
replicates for each experiment is indicated in figure legends. Statistical differences were 
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assessed using paired Student’s t-test to compare AAV1 treatment effect on contralateral 
muscles and for whole body weight or glucose levels within the same animal. Two-way 
ANOVA was performed to test for the interaction between NDRG2 overexpression and fasting. 
Post-hoc analysis using Multiple t-tests with a Sidak's multiple comparisons test as well as t-
tests were performed to locate the differences when a significant interaction was observed. 
Analyses were performed using GraphPad Prism (GraphPad Software version 7, La Jolla, CA, 
USA). Data were considered statistically significant at p <0.05. 
 
 
4. 5. Results 
 
4. 5. 1. Confirmation of NDRG2 overexpression and phenotypic fasting 
effects 
 
To determine whether NDRG2 was overexpressed following AAV administration and to 
determine any fasting effect on endogenous NDRG2 levels, TA muscle lysates were analysed 
for mRNA and protein expression of NDRG2. Post 4 weeks, Ndrg2 mRNA (Figure 4.1A) and 
NDRG2 protein expression (Figure 4.1B) levels increased significantly by ~60% in AAV1-
mNDRG2 injected TA muscles compared to AAV1 null control. Similarly, post 8 weeks Ndrg2 
mRNA (Figure 4.2A) and NDRG2 protein (Figure 4.2B) increased by 40% in AAV1-
mNDRG2 muscles compared to AAV1-null controls. Interestingly, endogenous Ndrg2 mRNA 
levels at 4 weeks were higher in AAV1-mNDRG2 injected fasted muscle compared to fed 
mouse muscle (Figure 4.1A). However, protein levels at both 4 and 8 weeks (Figure 4.1B and 
4.2B) were comparatively higher in fasted mouse muscles compared to the fed mouse.  
Following 24 h of fasting, the body weights of the fasted mice decreased ~10% compared to 
their fed state post 4 (Figure 4.3A) and 8 weeks (Figure 4.3B). Serum glucose levels also 




Figure 4. 1. Gene and protein expression of NDRG2 in TA muscles of fed and 24 h fasted 
mice 4 weeks post AAV1-NDRG2 treatment. (A) Ndrg2 mRNA expression levels (A) and 
NDRG2 protein level (B) in AAV1-null control (C; black bars) and AAV1-mNDRG2 treated 
muscle (N; grey bars). Data represents n=6 mice per group. ****p<0.0001 to AAV1-null and 




Figure 4. 2. Gene and protein expression of NDRG2 in TA muscles of fed and 24 h fasted 
mice 8 weeks post AAV1-NDRG2 treatment. (A) Ndrg2 mRNA expression levels (A) and 
NDRG2 protein level (B) in AAV1-null control (C; black bars) and AAV1-mNDRG2 treated 
muscle (N; grey bars). Data represents n=6 mice per group. ****p<0.0001 to AAV1-null and 





Figure 4. 3. Body weight and serum glucose levels following 24h fasting post 4 and 8 weeks 
of AAV1-mNDRG2 treatment. Total body weights of fasted mice post 4 (A) and 8 (B) weeks 
of overexpression. Serum glucose levels of fed and fasted mice at the start and after 24h 




4. 5. 2. The effect of NDRG2 and fasting on TA muscle mass and fibre-type 
The TA muscle weights had decreased by approximately 5% in AAV1-NDRG2 treated 
compared to AAV1-null control treated mice both 4 weeks (Figure 4.4A, p<0.001 for both the 
fed and fasted groups) and 8 weeks post injection (Figure 4.5A, p<0.001). As a small significant 
decrease in muscle mass of AAV1-NDRG2 treated TA muscle was measured, muscle fibre 
type and cross-sectional area of the fibres were assessed as well as evidence of fibre 
regeneration. Moreover, as no fasting effect was observed on muscle weight, only fed mouse 
muscles are shown for fibre type analyses (Figure 4.6A). Fibre type distribution and area in 
fasted muscles is shown in (Appendix Figure 4).  Fibre type distribution (Figure 4.4D), cross 
sectional area (Figure 4.4E) and mRNA levels of myosin heavy chain genes, MHC2a, MHC2b 
and MHC2x (Figure 4.4B) were not affected by either NDRG2 overexpression or fasting. 
Representative microscopy images used for fibre type analysis and representative whole TA 
muscle images are shown in Figure 4.6A. No visual evidence of myofibre regeneration as 
represented through the presence of centrally located nuclei was observed with NDRG2 




Figure 4. 4.  Effect of NDRG2 overexpression on TA muscle weight and fibre types/area 
post 4 weeks AAV1-mNDRG2 treatment. TA weights (A), myosin heavy chain gene 
expression fed (B) and fasted (C), fibre type distribution (D) and minimal Feret’s diameter 
(E)  in AAV1-null control (black bars) and AAV1-mNDRG2 treated muscle (grey bars). Data 
































































































































Figure 4. 5.  Effect of NDRG2 overexpression on TA muscle weight and fibre types/area 
post 8 weeks AAV1-mNDRG2 treatment. TA weights (A), myosin heavy chain gene 
expression in fed (B) and fasted (C), fibre type distribution (D) and minimal Feret’s diameter 
(E)  in AAV1-null control (black bars) and AAV1-mNDRG2 treated muscle (grey bars). Data 







































































































































Figure 4. 6. Representative immunohistochemistry microscopy images of whole TA and H & 
E images of fed and fasted mice following NDRG2 overexpression. TA tissue sections of fed 
and fasted mice with 4 weeks AAV1 treatment or for 8 weeks AAV1 treatment in fed mice 
following MHC fibre type immunostaining (A) and fibre regeneration observation (B) C,  
AAV1-null control; and N, AAV1-mNDRG2. Scale bar = 200 µm for MHC images and 100 
µm for H&E images.
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4. 5. 3. Impact of NDRG2 overexpression on muscle protease pathways 
The mRNA expression of the ubiquitin proteasome E3 ligase genes, atrogin-1(Figure 4.7A and 
4.8A) and MuRF1 (Figure 4.7B and 4.8B), but not Trim32 (Figure 4.7C and 4.8C), was induced 
5 to10-fold in fasted muscles; however, no influence of NDRG2 overexpression post 4 and 8 
weeks was observed. The lipidation of autophagic marker LC3, from LC3-I to LC3-II, 
measured by the ratio of LC-II/LC3-I also increased by 5 % in fasted mouse muscles at both 4 
(Figure 4.7E) and 8 weeks post treatment (Figure 4.8E). No difference was found in caspase 3 
levels between fed and fasted muscles at both 4 and 8 weeks post injection and no impact of 
NDRG2 overexpression was observed on LC3 lipidation and caspase 3 cleavage (Figure 4.7E 
and 4.8E). Calpain activity was marginally increased in fasted muscles with NDRG2 
overexpression compared to fasted AAV1-null control and fed AAV1-mNDRG2 treated 
muscles post 4 weeks (Figure 4.7D). However, at 8 weeks calpain activity remained unchanged 







Figure 4. 7. Gene and protein expression of proteasomal markers and calpain activity in TA 
muscles of fed and fasted mice following 4 weeks of NDRG2 overexpression. The mRNA 
expression levels of Atrogin-1 (A), MuRF1 (B) Trim32 (C), the activity of calcium 
dependent proteases (D), calpains, measured in fluorescence units (FU) in AAV1-null control 
(C; black bars) and AAV1-mNDRG2 treated muscle (N; grey bars). Protein expression of 
LC3-I, LC3-II (represented as LC3-II/LC3-I ratio) and caspase 3 (E). Data represent n=6 
mice per group, #### and ****p< 0.0001, ### and ***p<0.001 as well as ## and **P<0.01 to 

























































































































































                                    
 
Figure 4. 8. Gene and protein expression of proteasomal markers and calpain activity in TA 
muscles of fed and fasted mice following 8 weeks of NDRG2 overexpression. The mRNA 
expression levels of Atrogin-1 (A), MuRF1 (B) Trim32 (C), the activity of calcium 
dependent proteases (D), calpains, measured in fluorescence units (FU) in AAV1-null control 
(C; black bars) and AAV1-mNDRG2 treated muscle (N; grey bars). Protein expression of 
LC3-I, LC3-II (represented as LC3-II/LC3-I ratio) and caspase 3 (E). Data represent n=6 








































































































































































       
4. 5. 4. Impact of NDRG2 overexpression on protein translation initiation 
complex factors  
 
Proteins levels of phosphorylated eIF4E proteins increased significantly in the fasted state 
compared to fed mouse muscles at both 4 (Figure 4.9) and 8 (Figure 4.10) weeks post NDRG2 
treatment. Phosphorylated 4EBP1 protein levels were significantly lower in the fasted 
compared to fed mouse muscles at both 4 (Figure 4.9C) and 8 (Figure 4.10C) weeks post 
NDRG2 overexpression. Moreover, no effect of NDRG2 overexpression at 4 or 8 weeks post 
AAV1-mNDRG2 treatment was observed on phosphorylated protein levels of eIF4E and 










Figure 4. 9. Protein expression of translation initiation complex markers in TA muscles of 
fed and fasted mice following NDRG2 overexpression at 4 weeks. Immunoblot 
representation (A) and protein expression levels of phosphorylated p-eIF4E (B) and 
phosphorylated p-4EBP1 (C) in AAV1-null control (C; black bars) and AAV1-mNDRG2 
treated muscle (N; grey bars). Data represent n=6 mice per group, ** represents p<0.001 and 









Figure 4. 10. Protein expression of translation initiation complex markers in TA muscles of 
fed and fasted mice following NDRG2 overexpression at 8 weeks. Immunoblot 
representation (A) and protein expression levels of phosphorylated p-eIF4E (B) and 
phosphorylated p-4EBP1 (C) in AAV1-null control (C; black bars) and AAV1-mNDRG2 
treated muscle (N; grey bars). Data represent n=6 mice per group, *** represents p< 0.001* 









4. 5. 5. Impact of NDRG2 overexpression on MAPK and AMPK pathways 
Protein levels of phosphorylated p38 MAPK were increased in fasted muscles at 4 weeks, 
however, total p38 MAPK was not altered following NDRG2 overexpression or fasting post 4 
(Figure 4.11) and 8 weeks (Figure 4.12). The levels of phosphorylated p38 normalized to total 
p38 protein levels were increased in fasted mouse muscle following NDRG2 overexpression 
for 4 weeks (Figure 4.11D) and 8 weeks (Figure 4.12D). 
 
 
Figure 4. 11. Protein expression of MAPK and AMPK pathway markers in TA muscles of 
fed and fasted mice following NDRG2 overexpression at 4 weeks. Immunoblot 
representation (A) and protein expression levels phosphorylated p-p38 MAPK (B), total p38 
MAPK (C), phosphorylated p-AMPKα (D) and phosphorylated p38 normalized to total p38 
levels (E) in AAV1-null control (C; black bars) and AAV1-mNDRG2 treated muscle (N; 










Figure 4. 12. Protein expression of MAPK and AMPK pathway markers in TA muscles of 
fed and fasted mice following NDRG2 overexpression at 8 weeks. Immunoblot 
representation (A) and protein expression levels of phosphorylated p-p38 MAPK (B), total 
p38MAPK (C), phosphorylated p-AMPKα (D) and phosphorylated p38 normalized to total 
p38 levels (E) in AAV1-null control (C; black bars) and AAV1-mNDRG2 treated muscle (N; 








4. 6. Discussion 
This study aimed to determine the effect of NDRG2 overexpression on mouse muscle mass 
and adaptation through alterations in stress response pathways under basal and fasting 
conditions. In 24 h fasted mice, body weight and serum glucose levels decreased whereas the 
expression of genes and proteins linked to the ubiquitin proteasome, autophagy, protein 
translation and MAPK/AMPK pathway, and activity of calpains all increased significantly as 
did endogenous NDRG2 levels. Although muscle mass did not decrease in the fasted mice, the 
TA muscles with NDRG2 overexpression weighed less compared to respective controls 
irrespective of the fed or fasted condition. Despite the loss in muscle mass, no further effect by 
NDRG2 on fibre-type or diameter or on signalling proteins linked to stress, protein degradation 
and protein translation pathways was found under basal or fasting conditions.  
Decreased muscle mass and body weight ensue with extended fasting or nutrient restriction 
(93). This decrease is due to reduced protein synthesis and increased degradation to enable a 
source of amino acids for oxidation in muscle to meet energy demands (330, 341). Previously 
a 14 % decrease in total body weight and a 7.5 % decrease in gastrocnemius muscle (328) have 
been reported with 24 h fasting in mice in addition to a 58 % decrease in blood glucose levels 
(341). Our study presents similar findings with 10% and 50% decrease in total body weight 
and serum glucose levels in fasted mice, respectively. However, TA muscle weights remained 
unchanged after fasting. This might be due to the differential impact of fasting on different 
muscles despite both of these muscles have a high proportion of MHC2b and MHC2x (342), 
which are more susceptible to atrophy under fasting condition (4, 343). 
Skeletal muscle is an adaptive tissue and is responsive to acute stress such as nutrient 
deprivation. These adaptations are brought about by multiple pathways including changes in 
MHC gene expression and/or shift in fibre type (4, 344). Expression of MHCs is regulated by 
multiple factors and in C2C12 myotubes, NDRG2 overexpression leads to decreased levels of 
genes coding for MHC2x and MHC2b (177). However, as shown in this study, it does not 
appear that elevated NDRG2 levels affect myosin heavy chain gene or fibre-type expression in 
vivo. Moreover, NDRG2 transcripts have been associated with pathological cardiac muscle 
hypertrophy (345). However, no impact of increased NDRG2 levels on fibre MHC expression, 







have not been sufficient to disrupt skeletal muscle homeostasis in terms of muscle fibre 
composition and size at least in the TA muscles.     
Proteasomal degradation of most proteins requires their ubiquitination by specific ubiquitin 
(E3) ligases. These include the muscle-specific E3 ligases, atrogin-1 and MuRF1 (70, 71, 346). 
These two E3 ligases are similarly upregulated in disparate muscle atrophies including 
denervation, dexamethasone and fasting (41). Moreover, mRNA levels of atrogin-1 and 
MuRF1 have been shown to increase dramatically in cancer cachexia, diabetes, renal failure 
and fasting in mice (119). In addition to these, Trim32 is another ubiquitin ligase particularly 
required for thin filament degeneration but is not induced upon fasting (74). Here, this study 
reports an increase in mRNA expression of atrogin-1 and MuRF1 as expected, and Trim32 
remained unchanged in fasted compared to the fed mouse muscles, hence validating previous 
findings. In addition to ubiquitination, muscle proteins are degraded through autophagy which 
is activated in fasting. LC3 has previously been demonstrated to increase in muscles of mice 
fasted for up to 3 days wherein LC3-I is lipidated to LC3-II increasing the ration of LC3-
II/LC3-I (78, 79, 83). Similarly, this study found increased LC3-II/LC3-I ratio in fasted mouse 
muscles both at 4 and 8 weeks of NDRG2 overexpression. Autophagy and protein translation 
is also activated by AMPKα (347, 348) and p38 MAPK (349, 350) through targeting multiple 
pathways in cellular stressed conditions including fasting and re-feeding in other species (351) 
and other tissues (352). An increase in phosphorylated p38 MAPK was identified here with 
fasting; however, no difference in phosphorylated levels of AMPKα were found in this study. 
A third protein degradation mechanism is through calcium activated cysteine proteases, 
calpains, which are activated in muscle wasting conditions including fasting (353). NDRG2 
increased calpain activity marginally in fasted muscles and this could explain the reduced 
weights of TAs with increased NDRG2 expression levels in fasting condition at least. Given 
that only a marginal decrease of muscle weights was recorded, only a slight increase in calpain 
was observed.  
Protein synthesis rates in muscle decline during fasting mainly through decreased translation 
initiation (117). Activator of translation initiation, eIF4E is downregulated and its inhibitory 
binding protein, 4EBP1 is upregulated during fasting (119, 328). However, in this study 
increased and decreased levels of phosphorylated eIF4E and 4EBP1, respectively, were 







from previous studies are based on microarray gene expression results, which may not be true 
when determined at the phosphorylated state of the proteins. Moreover, the increased levels of 
phosphorylated p38 were found in fasted muscle but AMPKα levels remained unchanged 
during fasting as well as following NDRG2 overexpression. Phosphorylation of p38 increases 
during fasting and has been associated with increased MuRF1 expression in myotubes and 
muscles (351).  
The increased levels of endogenous NDRG2 in fasted mouse muscles may indicate the stress 
responsive and adaptive role it plays under atrophying conditions. On the other hand, NDRG2 
overexpression may have reached saturation levels and hence demonstrated a ceiling effect, 
which could explain no further influence on most of the parameters measured in this study 
following NDRG2 overexpression. Furthermore, during in vivo intervention, actual 
physiological conditions are at play while as in vitro does not have all physiological systems 
acting together  
Therefore, the results demonstrate that NDRG2 overexpression decreased muscle mass 
marginally, however, did not alter stress signalling pathways controlling muscle wasting, 





















































5. 0. Effect of NDRG2 overexpression on oxidative and ER stress 
in SOD1G93A ALS mouse muscle 
   
5. 1. Abstract 
Increased and sustained expression of mutant superoxide dismutase 1 (SOD1G93A) leads to the 
development of the motor neurone disease, amyotrophic lateral sclerosis (ALS). Associated 
with ALS development is oxidative and ER stress, mitochondrial dysfunction and muscle 
weakness in skeletal muscle. NDRG2 is a stress responsive gene that protects mouse myoblasts 
against H2O2-induced oxidative and ER stress. A proof-of-concept study investigated whether 
NDRG2 overexpression would mitigate elevated reactive oxygen species (ROS) levels or 
protein markers of ER stress in the skeletal muscle from SOD1G93A ALS mice. At 80 days of 
age, the right tibialis anterior (TA) muscle of wild type (WT) and SOD1G93A mice was injected 
with an adeno-associated virus containing mouse NDRG2. The left TA muscle was injected 
with a control virus. Disease progression was monitored by rotarod balance performance. Four 
weeks post injection, mice were humanely killed and TA muscles harvested. In SOD1G93A 
mice, when compared with WT mice, endogenous NDRG2 protein, ROS, markers of ER stress 
and apoptosis, including transcription factor C/EBP homologous protein, binding 
immunoglobulin protein, inositol-requiring enzyme 1- alpha and caspase 3, as well as 
mitochondrial citrate synthase protein levels, were all elevated. Muscle weights were 







above mentioned measurements indicating that NDRG2 does not mitigate ROS, ER stress or 
skeletal muscle mass in SOD1G93A ALS mice. 
 
5. 2. Introduction  
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the death 
of motor neurons leading to muscle wasting, paralysis and death within 2-3 years of onset 
(354). The majority of ALS cases are sporadic, and the 10-20% of genetic cases are classified 
as familial (FALS). A number of studies have demonstrated increased oxidative stress (OS) in 
ALS pathogenesis as elevated levels of 3-nitrotyrosine, a marker for oxidative damage, were 
found in post-mortem tissues of patients (355-357). The cause of the disease is unidentified in 
most ALS cases, however, mutations in a number of genes have been associated with the 
progression of the disease (358). The first mutated gene identified in FALS was copper/zinc 
superoxide dismutase 1 (SOD1), located on chromosome 21, and over one hundred individual 
mutations associated with ALS pathogenesis have been identified in this gene (359). SOD1 is 
an antioxidant enzyme that maintains superoxide concentration produced by skeletal muscle at 
a steady level under basal conditions (138, 360). Hence, mutations in SOD1 can lead to 
increased oxidative stress, which is one of the factors believed to be involved in ALS (127). 
The SOD1 mutations in mouse models of ALS are characterized by strong associations 
between oxidative and ER stress and disease onset (158). SOD1G93A is a transgenic mouse 
model of ALS with a mutation where glycine 93 is changed to alanine. In SOD1G93A mice 
reduced muscle mass (361) and increased oxidative stress (362) is found as early as 8 weeks 
of age. This suggests that skeletal muscle can be precociously affected in ALS in a manner 
independent of the denervation process of degenerating motor neurons. Skeletal muscle 
specific overexpression of mutant SOD1G93A not only increases oxidative stress, impairs 
mitochondrial function and decreases muscle mass, but also elevates ROS levels, stimulates 
neuromuscular junction abnormality, axonopathy, motor neuron degeneration and motor 
neuron death (80, 145, 158). Skeletal muscle damage becomes evident by 10 weeks of age in 
SOD1G93A mice. By 16 weeks of age muscle force, muscle fibre cross-sectional area and fibre 







digitorum longus (EDL) muscle (80, 158, 363). In addition to muscle atrophy, these transgenic 
mice exhibit higher levels of ROS (80) and increased mitochondrial damage (158). 
Although ER stress is a short and homeostatic event, sustained elevation of ER stress levels 
can cause apoptosis through specific pathways. For example, in gastrocnemius muscle from 
SOD1G93A mice at 70 and 120 days of age IRE1a and BiP, both ER stress sensors and CHOP, 
an ER specific-apoptotic signalling protein, are upregulated (158). These studies provide 
evidence for muscle-to-motor neuron dying-back processes and reveal that skeletal muscle is 
a direct target of SOD1G93A mediated toxicity. However, the mechanisms through which SOD1 
mutation confers toxicity and how that stress-induced toxic insult modulates various pathways 
to cause disease are incompletely explored. Importantly, a recently approved drug treatment, 
edaravone, which functions as a free radical scavenger and an antioxidant, reduces oxidative 
stress levels and slows the advance of ALS (135). These observations support the notion that 
alleviating symptoms such as oxidative and ER stresses may improve the health and well-being 
of patients living with ALS. 
 
The N-myc downstream-regulated gene 2 (Ndrg2) gene is linked to the proliferation, 
differentiation and stress responses in various cell and tissue types (159-161). In skeletal 
muscle, Ndrg2 is upregulated and downregulated in C2C12 myotubes treated with catabolic 
and anabolic stress agents, respectively (176). Moreover, overexpressing NDRG2 protects 
C2C12 myoblasts against H2O2-induced OS and ER stress (179).  This is supported by reduced 
apoptosis and ER stress markers, including poly ADP ribose polymerase and caspase 3 
cleavage, as well as an increase in pro-survival B cell leukemia/lymphoma 2 and Bcl-2-
associated X protein levels (179).  However, whether NDRG2 reduces oxidative and ER stress 
in vivo is yet to be investigated.  Therefore, the aim of this study was to investigate whether 
increasing NDRG2 in the tibialis anterior muscle of SOD1G93A transgenic mice would attenuate 
oxidative and ER stress.  








5. 3. Materials and methods 
 
5. 3. 1. Adeno-associated virus serotype 1 (AAV1) production 
The AAV1 expressing mouse NDRG2 (AAV1-mNDRG2) and empty AAV1 control vector 
(AAV1-null) under the control of the polymerase II CMV promoter were generated by Vector 
Biolabs (Great Valley Parkway, Malvern, PA 19355). 
 
5. 3. 2. Intramuscular injections of AAV1-mNDRG2 and AAV1-null 
This project was approved by the Deakin University Animal Ethics Committee (ethics project 
code: G23-2015). Female SOD1G93A transgenic mice bred on a C57BL/6 background and wild-
type (WT) C57BL/6 littermates were sourced from Macquarie University, Australia. Mice were 
housed at room temperature of 21 ± 2 oC, humidity between 40-70% with a 12-hour light/dark 
cycle. Animals were monitored daily and disease progression assessed on a weekly basis 
through neuroscoring and rotarod performance. At approximately 80 days of age, mice were 
anaesthetised with isoflurane to induce general anaesthesia. NDRG2 was overexpressed using 
AAV1 viral vectors driven by a CMV promoter in Chapter 2. Using the same approach, 
NDRG2 overexpression will be achieved by intramuscularly injecting 5x1010 vector genome 
(vg) of AAV1-mNDRG2 diluted in saline into the right TA (N) muscle. The contralateral left 
TA (C) muscle was injected with the same concentration of control AAV1-null in saline. The 
mice were humanely killed four weeks post injection and TA muscles were collected and 
weighed prior to freezing in isopentane chilled with liquid nitrogen and storage at -80oC. For 
further analyses, muscles were homogenised in chilled 1 x RIPA buffer (25mM Tris•HCl pH 
7.6, 150mM NaCl, 1% [v/v] NP-40, 1% [v/v] sodium deoxycholate, 0.1% [v/v] SDS) (Merck 
Millipore, North Ryde, NSW, AUS) with protease inhibitors (1 μl/ml) (Sigma–Aldrich, NSW, 
AUS) and Halt Phosphatase Inhibitor Single-Use Cocktail (ThermoFisher Scientific, Scoresby 
VIC, AUS). The protein concentration of the soluble protein lysate was determined using 








5. 3. 3. Neuroscoring and Rotarod performance 
Neuroscoring was determined based on the phenotypic screening protocol previously 
developed and described (364). Briefly, mice were held from the base of tail 1.5 inches above 
the cage and away from chow for 1-3 seconds, repeated 3 times while observing hind limbs. 
Respectively, a neuroscore of 0, 1, 2 or 3 was given if hindlimbs were fully extended away 
from the lateral midline without any shaking, trembling and partial collapsing towards the 
midline, hindlimb completely collapsed with no extension or complete paralysis and extensive 
shaking.  
Motor performance was measured using the rotarod (Model no, 47650, Ugo Basile, Italy) as 
described previously (365, 366) with minor modifications. For this test, mice were placed on a 
cylindrical dowel for 5 min, two times to allow them to acclimatize to the test apparatus. Once 
the test started, the cylindrical dowels commenced rotating with acceleration from 5 - 20 rpm 
up to 180 s. Mice were put onto the rod facing towards the rotation and were required to walk 
in a forward direction on the rotating dowel. If the mice were no longer able to walk on the 
rotating dowel, they fell onto the landing platform below. This triggered the end of the trial for 
the animal and measurements of time to fall were collected. After a 5 min rest, the mice 
underwent a second performance run and the longest time to fall measurement out of the two 
performance tests was recorded. Rotarod performance was assessed weekly from 70 days of 
age after an initial familiarisation test until the end of the experiment five weeks later.  
 
5. 3. 4. Western Blotting  
Details of antibodies measuring protein markers of mitochondrial function, ER stress and 
apoptosis are provided in Table 5.1. Twenty or forty micrograms of each protein lysate sample 
were analysed using a standard western blotting method first involving the electrophoresis of 
the samples using Criterion stain-free SDS-PAGE gels by running at 180 V on the Mini-
PROTEAN 3 cell (Bio-Rad) with electrophoresis buffer (25 mM Tris-base, 200 mM glycine, 
0.1% sodium dodecyl sulphate (SDS)). Proteins were then transferred to a 0.45 μm Immobilin-
P (Millennium science) using the Mini Trans-Blot electrophoretic transfer cell (Bio-Rad) with 
transfer buffer (25 mM Tris-base, 192 mM glycine, 10% methanol) at 100 V for 1 hour. Prior 







protein loading using Image labTM 6.0 software. Membranes were blocked in 1:1 Odyssey 
blocking buffer and Tris-buffered saline (TBS; 40 mM Tris, 273 mM sodium chloride) and 
incubated in the primary antibody overnight at 4ºC. Membranes were then washed with TBS 
and 0.1% Tween-20 (Astral Scientific) (TBST) and probed with the secondary antibodies, goat 
anti-rabbit AlexaFluor®680 or donkey anti-mouse AlexaFluor®800 IgG antibodies (Life 
Technologies) diluted at 1:10,000 in 50% TBS, 50% Blocking Buffer (Li-COR Biosciences, 
Lincoln, NE, USA), 0.01% SDS. Membranes were exposed on the ODYSSEY® Infrared 
Imaging System (Millennium science). Densitometry analysis was performed using Image 
Studio™ Lite software (LI-COR Biosciences). Protein expressions were normalized to total 
protein quantified in each lane. 
 
Table 5. 1. Antibodies used for protein expression determination through western blot 
 
Antibody Antibody Type Dilution Catalogue No.  Company 
PGC1-α Rabbit Polyclonal 1:1000 #516557 Merck Millipore 
Citrate Synthase Rabbit Poly. 1:1000 #14309 Cell Signalling 
CHOP Mouse Monoclonal 1:1000 #2895T Cell Signalling 
BiP Rabbit Poly. 1:1000 #3177T Cell Signalling 
IRE1α Rabbit Poly. 1:1000 #3294S Cell Signalling 
Caspase 3 Rabbit Poly. 1:1000 #9662S Cell Signalling 
NDRG2 Rabbit Poly. 1:5000 #HPA002896 Sigma–Aldrich 
 
 
5. 3. 5. Citrate synthase (CS) activity   
CS activity in each protein sample was measured as described previously (367). The assay 
buffer contained 66 mmol/l Tris (pH 8.3), 0.6 mmol/l Acetyl CoA, 0.1 mmol/l DTNB and 0.6 
mmol/l oxaloacetate (added just before reading plates) (final concentrations) and 5 µg of 
homogenate of each protein sample diluted in 1x RIPA protein extraction buffer (Merck 







wavelength of 412 nm at 15s intervals for a period of 3 min using the Synergy 2 Multi-Mode 
microplate reader (BioTek, Winooski, VT USA). All measurements were performed in 
duplicate at 25°C. An extinction coefficient of 13,600 M-1cm-1 for DTNB was used for 
calculations and CS activity determined as described (368, 369) and was expressed as μmol 
per gram protein per minute. As CS protein content was higher in SOD1G93A muscles compared 
to WT muscles, the CS activity was normalized to the total CS protein content as quantitated 
by western blotting analyses and reported in as micromoles per minute per milligram protein. 
 
5. 3. 6.  2’, 7’– Dichlorodihydrofluorescein (DCFH) assay 
Ten micrograms of each protein sample lysate diluted in 290 μl DCFH assay buffer, and added 
in duplicate to 96-well fluorescent plates (130 mmol/l KCl, 5 mmol/l MgCl2, 20 mmol/l 
NaH2PO4, 20 mmol/l tris-HCl and 30 mmol/l D-glucose, pH 7.4 (370). The reaction was 
initiated with the addition of 1.2μl DCFH-DA (2, 7-Dichlorodihydrofluorescein diacetate; 
Cayman Chemicals) dissolved in methanol (5 μmol/l final concentration). For the deacetylation 
of DCFH-DA to DCFH by sample esterases, plates were incubated at 37°C for 15 min in the 
dark. DCFH is then rapidly oxidized to fluorescent DCF when in the presence of ROS and 
reactive nitrogen species (371). The rate of change of fluorescence was measured using a 
Synergy 2 Multi-Mode microplate reader (BioTek) with an excitation wavelength of 485 nm 
and an emission wavelength of 528 nm over 60 min. The rate of sample fluorescence change 
was linear for the initial 60 minutes. After 60 min, 1667 μmol/l H2O2 was added to all samples 
causing a rapid increase in fluorescence in all samples that increased linearly for at least 30 




5. 4. Statistics 
All data are reported as the mean ± standard error of the mean (S.E.M.). Statistical differences 
were assessed using two-way ANOVA with Sidak's multiple comparisons test to determine 
significant differences between muscles injected with AAV1-null control (C) or AAV1-







overexpression interaction with disease. Analyses were performed using GraphPad Prism 
(GraphPad Software version 7, La Jolla, CA, USA). Data were considered statistically 
significant at p <0.05. 
 
 
5. 5. Results  
 
5. 5. 1. Confirmation of NDRG2 overexpression and its endogenous levels in 
SOD1G93A and WT muscle 
 
TA muscle tissues were first analyzed to determine if NDRG2 was overexpressed. Western 
blot results confirmed that endogenous NDRG2 levels were significantly higher in SOD1G93A 
compared to WT muscles by more than 50% (Figure 5.1, p<0.05). Moreover, intramuscular 
injection of the AAV1-mNDRG2 virus into the TA further increased NDRG2 protein levels in 
both WT and SOD1G93A mice by 47% (p<0.05) and 39% (p< 0.01), respectively, when 
compared to AAV1-null control vector injected TA muscles.   
  
Figure 5. 1. Protein expression of NDRG2 in TA muscles of SOD1G93A and WT mice 







black bars) and  AAV1-mNDRG2 (N; grey bars) injected muscles. Data represent n=6 mice 
per group. ^p<0.05 and ^^p< 0.01 to respective AAV1-null control groups,  #p< 0.05 to WT- 
AAV1-null control and **p< 0.01 to WT-AAV1-mNDRG2. 
 
5. 5. 2. Assessment of disease progression through the determination of 
motor neuron coordination and muscle weight 
 
To assess disease progression in the SOD1G93A mice, motor performance and balance (366) 
was assessed at around 70 days of age and then weekly for 5 further weeks.. Wild type mice 
remained on the rotarod for the required time in most cases. However, SOD1G93A mice could 
not remain on the rotarod for more than 120s for the first 3 weeks. The time on the rotarod 
decreased by 42% and 47 % (p<0.0001) by week 4 and 5 respectively (Figure 5.2A). The 
neuroscore for the SOD1G93A mice was 1 at the early symptomatic stage. This increased 
significantly (p<0.0001) to 2 and 3 as the disease progressed. The WT mice maintained a score 
of zero throughout the experimental period (Figure 5.2B). As ALS ensues with loss of skeletal 
muscle mass and function, the average TA muscle weight (Figure 5.2C) was recorded. The 
average TA muscle weight of the SOD1G93A mice was 50% lower (p<0.0001), when compared 









Figure 5. 2. Disease progression in SOD1G93A transgenic mice. Rotarod performance (A) and 
Neuroscore (B) of WT and SOD1G93A mice from 70 days of age over 5 weeks. Average TA 
muscle weights of WT and SOD1G93A mice (C) 4 weeks post injection of NDRG2 in AAV1-
null control (black bars) and  AAV1-mNDRG2 (grey bars) injected muscles. Data represents 
n=6. ^^ represents p< 0.0001 to WT at a particular week,  #### represents p<0.0001 to 
SOD1G93A - AAV1-null control and **** p< 0.0001 to WT-AAV1-mNDRG2. 
 
 
5. 5. 3. Impact of NDRG2 overexpression on ER stress and apoptotic 
markers 
  
The in vivo impact of NDRG2 overexpression on ER stress protein markers was assessed in 







muscles (Appendix Figure 5), protein expression measured by western blot were normalized 
to total protein levels (Appendix Figure 5). ER stress markers, BiP and CHOP, and pro-
apoptotic Caspase 3 (35 kDa subunit) protein levels were significantly higher (p< 0.0001) in 
SOD1G93A mice compared to WT; IRE1α levels were not different between groups (Figure 
5.3A and 5.3B). Furthermore, NDRG2 overexpression did not influence ER stress and 
apoptotic markers in WT or SOD1G93A mouse muscle (Figure 5.3B). 
 
Figure 5. 3. Protein expression of ER stress and apoptotic markers in TA muscles of 
SOD1G93A and WT mice following NDRG2 overexpression. Western blot results of ER stress 







black bars) and  AAV1-mNDRG2 (N; grey bars) injected muscles. Data represents n=6 mice 
per group. ####p<0.0001 to WT- AAV1-null control and ****p< 0.0001 to WT-AAV1-
mNDRG2 
 
5. 5. 4. Effects of NDRG2 overexpression on mitochondrial function and 
ROS production  
 
The effect of NDRG2 overexpression on ROS production, citrate synthase (CS) activity and 
markers of mitochondrial function were investigated. The protein expression of PGC1-α 
remained unchanged (Figure 5.4B) while as CS levels (Figure 5.4C, p< 0.0001) and ROS 
production determined through DCFH assay (Figure 5.4F, p< 0.0001) increased significantly 
in SOD1G93A mouse muscles compared to WT. CS activity was not different between 
SOD1G93A and WT mouse muscles when normalized to total protein in the sample (Figure 
5.4D) but was significantly reduced in SOD1G93A (Figure 5.4E, p< 0.001) after normalization 
with CS total protein levels. Overexpressing NDRG2 levels did not affect PGC1-α protein 










Figure 5. 4. PGC1-α and Citrate synthase protein levels in TA muscles of WT and SOD1G93A 
mice following NDRG2 overexpression. Western blot images (A) and quantification results 
of  PGC1-α (B) and citrate synthase (C) in AAV1-null control (C; black bars) and  AAV1-
mNDRG2 (N; grey bars) injected muscles. CS activity when equal amounts of muscle protein 
homogenate were taken (D) and that was normalized to total citrate synthase protein 
measured through western blot (E) in WT and SOD1G93A. ROS production determined 







group. ####p<0.0001 and ##p<0.01 to WT- AAV1-null control, ****p< 0.0001 and 
**P<0.01 to WT-AAV1-mNDRG2 
 
5. 6.  Discussion  
This proof-of-concept study aimed to determine whether NDRG2 overexpression could 
attenuate elevated ROS and ER stress markers, reduce muscle atrophy and improve 
mitochondrial function in the TA muscle of SOD1G93A ALS mice. The disease progressed as 
expected in the SOD1G93A mouse as indicated by increased neuroscore and latency to fall. ROS 
levels and ER stress protein markers as well as CS protein levels increased in SOD1G93A mouse 
muscles. Interestingly, endogenous NDRG2 levels also increased in SOD1G93A compared to 
WT mice. While NDRG2 overexpression was achieved, it did not alleviate oxidative and ER 
stress levels in SOD1G93A mouse TA muscle. 
The determination of disease progression in SOD1G93A mouse as reported previously (365, 372, 
373) was confirmed through neuroscoring and rotarod test performance. Initially, at around 70 
days of age, performance on the rotarod was similar between SOD1G93A and WT; however, as 
the disease progressed, reduced balance in the SOD1G93A mice increased over time as well as 
the neuroscore from 1 to 2 and finally to 3 demonstrating disease severity (365). WT mice 
remained zero score and no loss in balance revealing normal motor coordination.  
ER stress and apoptosis increased and loss in TA muscle weights in SOD1G93A mice was as 
demonstrated previously (158). IRE1α remained constant between SOD1G93A and WT muscles. 
Researchers have debated that essentially the phosphoryated IRE1α is upregulated with disease 
progression in SOD1G93A mice while unphosphorylated IRE1α remains unchanged between 
SOD1G93A and WT mouse muscle (374, 375). This could possibly explain why no difference 
in the expression levels of unphosphorylated IRE1α between diseased and wildtype animals 
was observed in this study. Hence, exploring whether phosphorylated levels consistently 
increase would help clarify the understanding of ER stress pathways involved in ALS 
pathogenesis. 
In order to measure a specific protein level in a sample, internal controls derived from 







samples. Actin and tubulin, two commonly used normalizing proteins in western blots can, 
however, be differentially expressed in tissues of animals and diseased animal models (376-
378) including muscle tissues (379), therefore, making them unsuitable to act as normalising 
proteins in SOD1G93A-affected muscle. Moreover, it is described that muscle atrophy from 
dennervation causes muscle fibre remodelling and enhanced protein synthesis (380) that may 
also affect normalizing protein expression.  Hence, normalizing with variable amounts of these 
control proteins could skew results and cause errors in analysis and conclusions. To address 
this discrepancy and to have protein levels accurately measured,  researchers have suggested 
that normalisation using total protein analysis provides a suitable way to eliminate this error 
(381). As total protein levels in SOD1G93A appeared comprehensively dissimilar compared to 
WT mouse muscles, we normalized protein expression of the proteins of interest with total 
protein levels to obtain accurate results. 
Citrate synthase activity and PGC1-α expression are used as markers of mitochondrial content 
and function. Past studies have shown CS mRNA and activity increase, decrease or remain 
unchanged in multiple skeletal muscle tissues of SOD1G93A mice and ALS patients (382-386). 
CS activity is reduced in the thigh, soleus and plantaris muscles of pre- and post-symptomatic 
SOD1G93A mice (383) and in vastus lateralis muscle of end-stage ALS patients (382). However, 
CS activity remains unchanged in gastrocnemius muscles at later stages (387). Similarly, 
inconsistent observations are found CS activity in muscles of ALS patients compared with age 
matched healthy controls, with some studies showing no difference (388) or increased levels 
(389, 390). In the spinal cord, CS activity did not change between transgenic SOD1G93A and 
WT animals (384, 391). In SOD1G86R mouse model of ALS, CS mRNA was unaffected at the 
early days of disease while as significantly reduced in TA muscles at the end stage of diseased 
life (386). Similarly, in TA muscle, CS mRNA levels in SOD1G93A were found comparable to 
WT at presymptomatic stage (392). These studies involved normalizing CS activity to equal 
muscle weights or equal protein input amounts in muscle homogenates, which may have 
contributed to the variability. Moreover, differences in CS levels may impact the activity levels 
and metabolism in the muscle tissues. Increased total CS protein levels in SOD1G93A TA muscle 
compared with WT were observed in this study. This is probably a reflection of the metabolic 
transition of muscle fibres from glycolytic to more oxidative type found here and reported 







fibres from fast glycolytic, to slow oxidative fibre types with more mitochondria, and hence, 
citrate synthase (136, 392).  Therefore, if  CS activity is normalized to relative CS protein 
levels, it gives an indication of the activity efficiency for the amount of CS protein present. 
Whereas normalizing to the total protein inputs reflects overall CS activity present within the 
muscle tissue. Another important regulator of mitochondrial function is PGC1-α, which 
contributes to the control of oxidative metabolism (394) and mitochondrial biogenesis (7). 
PGC1-α expression increases in SOD1G93A extensor digitorum muscles compared to wildtypes 
and is thought to promote fibre-type switching from glycolytic towards more oxidative fibres 
(80). However, no difference in PGC1-α levels was observed in this study.  
Basal NDRG2 protein levels were significantly higher in  SOD1G93A TA muscle compared to 
WT, which may be indicative of its role as a stress response protein. Alzheimer’s disease (AD) 
is another common neurodegenerative disease where NDRG2 is upregulated and associated 
with the pathogenesis of the disease (395). Moreover, elevated levels of NDRG2 protein were 
found in 15-month-old senescence-accelerated mouse (SAM) compared to 5-month-old SAM 
which further suggests the role of NDRG2 in the pathogenesis of ageing process (396). SAM 
mice are used as model organisms to study sarcopenia, age related loss in muscle mass and 
function which is driven by increased oxidative stress (397). The precise reason for elevated 
endogenous NDRG2 protein levels in SOD1G93A is unknown, but may be an unsuccessful 
attempt to attenuate intracellular ROS and ER stress as the disease progresses.  This elevated 
endogenous levels may be indicative of a saturation effect and explain why the further 
exogenous elevation of NDRG2 had no impact on oxidative and ER stress levels. However, it 
would be interesting to observe whether NDRG2 knockdown further increased OS stress levels 
and hence progression of the disease, or function as a therapeutic strategy to alleviate ALS 
symptoms.  
This study clearly demonstrated disease progression, manifested by functional measurements 
and analysis of several disease markers. However, a comprehensive analysis was somewhat 
limited as muscles of SOD1G93A mice are very small and stiff, which restricts sample amounts 
available for analyses. It could be worthwhile to increase the sample number to understand 







Therefore, it was concluded that, although endogenous NDRG2 levels were elevated in the TA 
muscle of symptomatic SOD1G93A mice,  further overexpression of NDRG2 did not alleviate 


























































Conclusions and future directions 
 
6. 1. Conclusions 
Skeletal muscle development begins during embryogenesis and ends soon after postnatal 
growth. This growth occurs predominantly through postnatal myogenesis and any defect can 
alter permanent function in later life. In adults, muscle mass may increase due to hypertrophy 
of existing muscle fibres or decrease owing to chronic stress and diseases, such as fasting and 
ALS, leading to muscle wasting. Muscle mass is influenced by protein turnover rates and fibre 
type composition. Genes and their protein products regulate these processes by activating or 
suppressing protein synthesis/degradation pathways as well as acting on various mechanisms 
involved in muscle mass maintenance through fibre type/size change and shift. In addition, 
miRNAs modulate myogenesis and also muscle mass by targeting protein products of genes 
during stress and diseased condition. The molecular mechanisms responsible for regulating 
muscle mass under basal and stress conditions in vitro and in vivo are not entirely understood. 
Hence, there is a need to delineate further the molecules that control muscle mass to develop 
effective therapeutic strategies to combat degenerative muscle conditions. N-myc downstream-
regulated gene 2 (Ndrg2) is a stress responsive gene, induced during myogenesis and catabolic 
conditions in myotubes (176). In addition, NDRG2 overexpression reduced protein synthesis 
under basal, but not in catabolic conditions, and protected myoblasts from oxidative and ER 
stress (177, 179). However, whether NDRG2 functions similarly in vivo and its physiological 
role, function and regulation have not been investigated previously. The general aim of this 
thesis was to understand the regulation of NDRG2 in vitro and in vivo and to define its role and 
function in acute and chronic muscle atrophy conditions, as seen via fasting and ALS, 
respectively.   
In conclusion, this thesis evaluated the regulation of NDRG2 in muscle cells and muscle tissue 
under atrophic conditions. In addition, this thesis extended previous in vitro findings to 







findings demonstrate that multiple miRNAs (miR-23a, -23b and -28) co-regulate each other 
and are likely required to suppress NDRG2 protein translation in muscle myotubes under 
catabolic stress conditions. Viral approaches using muscle specific promoters were unable to 
cause NDRG2 overexpression in neonatal muscle, while a CMV promoter increased NDRG2 
in adult mouse muscle. Moreover, NDRG2 levels increased in the muscle of SOD1G93A and 
fasted mice compared to WT and fed mice, respectively. Future investigation into miRNA 
regulation of NDRG2 in vivo under diseased conditions might unveil an avenue to treat muscle 
loss under stressed conditions. Moreover, as NDRG2 overexpressing muscles were smaller in 
healthy and muscle wasting conditions, knocking down NDRG2 in muscle atrophying 
conditions could further delineate its role in muscle mass regulation.   
 
6. 2. Future Directions 
6. 2. 1 Proposed study 1: Investigating the impact of the mimic mix on 
skeletal muscle mass in dexamethasone induced atrophy 
 
6. 2. 1. 1. Rationale 
In Chapter 2, it was demonstrated that overexpression of miR-23a, -23b and -28 simultaneously 
attenuated the dexamethasone-induced increase of NDRG2 protein translation. Previously, 
research has demonstrated that dexamethasone treatment increased NDRG2 levels in C2C12 
myotubes (176) in addition to increasing protein degradation, decreasing synthesis and 
activating autophagy, hence promoting muscle mass loss causing atrophy in rodent animals 
(111, 112, 114, 398, 399). Together, these studies suggest that the three miRNAs play a role in 
dexamethasone-induced muscle atrophy and will attenuate muscle mass loss via targeting and 
suppressing NDRG2 translation and may unfold a novel role for NDRG2 under such scenarios 








6. 2. 1. 2. Aim 
To determine whether combinatorial miRNA treatment will attenuate muscle mass loss in 
dexamethasone-induced atrophy in vivo. 
 
6. 2. 1. 3. Key methods 
Healthy adult mice will be treated with dexamethasone (Sigma-Aldrich, Castle Hill, NSW, 
AUS) as per the concentrations and time determined through dose-dependent manner as 
described in mice (102) and rats (398, 400). The effect of dexamethasone will be determined 
by weighing animals daily (398) and then the time decided for miRNA treatment (401, 402). 
Glucocorticoids including dexamethasone predominantly cause atrophy in fast-twitch type 2 
muscle fibres, 2X and 2B (107, 108). The TA muscle is suitable for miRNA treatment as, in 
addition to fast fibres, they also contain a high content of GC-receptors (109). Hence, miRNA 
mimics (described in chapter 2) will be injected into the TA muscle as detailed previously (214). 
Muscle tissues will be collected, weighed and analyzed for any difference in NDRG2 
expression, and the impact of the simultaneous overexpression of miR-23a, -23b and -28 on 
protein synthesis and degradation rates/pathways, autophagy and fibre type/size differences 
will be assessed. 
 
6. 2. 1. 4. Significance   
This study would validate in vitro observations of Chapter 2 in vivo and establish whether 
combinatorial miRNA treatment is able to attenuate increased NDRG2 levels in 
dexamethasone-induced muscle atrophy. Thus, future investigation into miRNA regulation of 
NDRG2 in vivo under diseased conditions might unveil an avenue to treat muscle loss under 
stressed conditions. 
 
6. 2. 2. Proposed study 2: Investigating the role of miR-28 in myoblast 








6. 2. 2. 1. Rationale 
MicroRNA-28 can regulate cell proliferation positively or negatively in various cancer cells. 
For example, miR-28 expression is upregulated in ovarian cancer and gastric tissues and can 
promote the progression of cell proliferation in ovarian (403) and gastric cancer cells (261). In 
contrast, its expression is down-regulated in renal cell carcinoma and B-cell lymphoma where 
its overexpression reduced the proliferation of renal carcinoma cells (404) and germinal centre 
B cells (405). MicroRNA-28 (404, 405) and NDRG2 (reviewed in (161)) may act as tumor 
suppressors by controlling cell cycle checkpoints. Furthermore, a recent study found miR-28 
upregulated in chronic lymphocytic leukemia cells, where miR-28 interacted with NDRG2 and 
increased mRNA and protein levels of NDRG2 when inhibited (406). 
NDRG2 expression increases during myogenic differentiation (176) and its overexpression 
increases myoblast proliferation (179). Moreover, in Chapter 2, it was demonstrated that miR-
28 and other two miRNAs targeted and reduced NDRG2 protein levels in muscle myotubes. 
MicroRNA-28 expression is linked to myogenesis. Transcriptome profiling has revealed miR-
28 upregulated in human myogenic differentiation (276), whether it controls myoblast 
proliferation is yet to be elucidated. Therefore, understanding how miR-28 would regulate 
NDRG2 during myogenic differentiation will help to delineate NDRG2 regulation in myoblasts. 
 
6. 2. 2. 2. Aim 
To determine the role of miR-28 in myoblast proliferation and its regulation of NDRG2 in 
myogenic differentiation.  
 
6. 2. 2. 3. Key methods 
The expression levels of miR-28 will be increased in C2C12 proliferating myoblasts using 
mimics and transient transfection approaches as described in Chapter 2. In addition, miR-28 
will be suppressed using locked nucleic acid inhibitors during the myogenic differentiation 







2 of this thesis, and the impact on proliferation rate will be determined through BrdU labelling 
(407). 
Moreover, as per the protocols our laboratory has established that using retroviral constructs,  
NDRG2 can be overexpressed (179) and suppressed (176) in muscle cells. The impact of 
altered NDRG2 levels on miR-28 expression and vice versa, will be determined to determine 
any philological interaction and regulation between these two molecules. The effects on the 
cell cycle will be unveiled through expression analyses of markers of negative and positive 
regulators of cell division. 
   
6. 2. 2. 4. Significance 
This study would define the role of miR-28 in myogenesis and hence differentiation of 
myoblasts. Moreover, it will help in understanding the regulation of NDRG2 by miR-28 in 
myoblasts proliferation. As muscle growth is regulated by myogenesis, this study may identify 
NDRG2 as a novel regulator of muscle cell proliferation in vivo. 
 
 
6. 2. 3. Proposed study 3: Investigating the effects of NDRG2 knockdown in 
normal and muscle atrophy conditions 
 
6. 2. 3. 1. Rationale 
NDRG2 was overexpressed in ALS mice (Chapter 5) and following fasting (Chapter 4) to 
determine its impact on the attenuation of muscle loss and pathways regulating muscle function. 
However, no influence was observed on different stress markers, pathways and muscle mass 
loss. A novel finding was that NDRG2 basal levels were higher in SOD1G93A mice compared 
to wildtype mice.  Therefore, it was concluded that NDRG2 overexpression might have reached 
a ceiling effect and increasing it further was unable to elicit additional function impact as 
observed in vitro. Hence, investigating the physiological role of NDRG2 by knocking it down 







6. 2. 3. 2. Aim 
To determine the impact of NDRG2 suppression on muscle mass under atrophic conditions. 
 
6. 2. 3. 3. Key methods    
The knockdown of NDRG2 will be achieved in adult mouse TA muscle by AAV1-shRNA 
technology as described (264, 408). Muscle atrophy will be induced either by nutrient 
deprivation for 24h or longer as muscle mass loss takes longer fasting. Body weights will be 
measured prior and post fasting followed by humanely sacrificing of mice, weight recording 
and tissue collection. Primarily, tissue samples will be analyzed for gene expression analyses, 
fibre type/size difference, protein degradation and protein synthesis signalling pathways 
activated during nutrient deprivation.  
 
6. 2. 3. 4. Significance 
This study would determine whether NDRG2 suppression is required to alleviate muscle mass 
loss in fasted adult mouse muscle. It will establish a novel NDRG2’s physiological and 
functional role in maintaining muscle mass and health under atrophic condition. Determining 
the function of NDRG2 in such scenario by knocking it down would be important as no study 
has looked at the impact of NDRG2’s reduction on muscle mass and function in vivo. 
 
6. 3. Future studies concluding remarks  
Although many studies are required, these proposed studies are a logical extension from the 
work presented in this PhD thesis and will further delineate the regulation and role of NDRG2 
in skeletal muscle under basal and catabolic stress conditions. Moreover, these future studies 
will extend the understanding of how miRNAs regulate NDRG2 both in vitro in myogenesis 
and in vivo under atrophic conditions. This information may lead to identifying novel 







conditions, defining its physiological role and function is required to determine whether it has 
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Appendix Figure 1. MiR-23a, -23b and -28 expression levels following miRNA transfection 
in C2C12 myotubes. Time-course in hours (h) of miR-23a, -23b and -28 expression levels 
following transfection of (A) miR-23a (dark grey bars), (B) miR-23b (light grey bars), and (C) 
miR-28 (white bars) compared to negative control (NC) miRNA (black bars) at 12, 24 or 48 h 
post transfection. Data are representative of two independent experiments with n=4 per sample 
group. **p<0.01 and ***p<0.001 to each NC per respective time point, and expression levels 













































































Appendix Figure 2. miRNA expression following combined miRNA mix transfection. 
MiRNA levels of (A) miR-23a (dark grey bars), (B) miR-23b, (light grey bars), and (C) miR-
28 (white bars) following transfection of miRNA mix or negative control miRNA (black bars) 
at 48 h post transfection. Data are representative of two independent experiments with n=4 per 
sample group. ***p<0.001 to NC, and expression levels are presented as arbitrary units (AU). 
 
 
Total protein levels in fed and fasted TA mouse muscles 
Total protein levels were determined through REVERT™ Total Protein Stain Normalization 
Protocol (Li-COR Biosciences, Lincoln, NE, USA) and measured using Image Studio Lite Ver 
5.2 (Li-COR Biosciences). Total protein levels for both 4 and 8 week treatment did not seem 






Appendix Figure 3. Total protein expression levels in fed and fasted mice following NDRG2 







panel) post AAV1-null control (C) and AAV1-mNDRG2 (N) treatment. Data represent n=6 
mice per group. 
 
 
Effect of NDRG2 overexpression on fibre type distribution and area in fasted 
mouse muscles 
 
Appendix Figure 4. Effect of NDRG2 overexpression on TA muscle fibre types/area post 4 
weeks AAV1-mNDRG2 treatment. Fibre type distribution (A) and minimal Feret’s diameter 
(B) in AAV1-null control (black bars) and AAV1-mNDRG2 treated muscle (grey bars). 
 
 
Total protein levels in TA muscles of SOD1G93A and WT 
The western blotting analysis was performed on TA muscle protein lysates to investigate 
protein expression of ER stress and apoptosis markers. Initial characterisation of the total 
protein profile from WT and SOD1G93A mice revealed that the protein content type is 
considerably different in SOD1G93A muscles compared to WT muscles (Appendix Figure 5A 
and 5B) indicating a clear disease impact on muscle tissue in SOD1G93A mice. Figure 5 
represents two SDS-PAGE gels run using the same samples that were used for subsequent 











Appendix Figure 5. Total protein expression levels in SOD1G93A and WT mice following 
NDRG2 overexpression. Gel-doc images of total protein levels in WT on blot left side and in 
SOD1G93A on right side in gel 1 (A) and gel 2 (B) of NDRG2 in AAV1-null control (C) and  











Appendix Table 1. Differential miRNA expression in skeletal muscle after exercise and disue 
miRNAs 
upregulated 
miRNAs downregulated Model Intervention duration References 
miR‐1, miR‐133a, miR‐9, miR‐23a, miR‐
23b, miR‐31 
Acute exercise Acute bout of moderate‐
intensity 
(409) 
miR‐133b, miR181a   Endurance cycling                               (409)
 miR‐1, miR‐133a Acute 
resistance 
exercise 
45 min of one‐legged 
knee extensor exercise 
(410) 
 miR‐1 Training with 
resistance 
exercise  
12 weeks (411) 
 miR‐1, miR‐133a, miR‐
133b, miR‐206 
Endurance Cycle ergometer five 
times/week for 12 weeks 
(412) 






204, miR‐330, miR‐345, 
miR‐375, miR‐449c, miR‐
483, miR‐509, miR‐520a, 
miR‐548, miR‐628, miR‐















101, miR-455, miR-144, 
miR-15b, miR-26b, miR-
28, miR-29b, miR-338, 
miR-92, miR-98, miR-451 
Endurance 
Training 
6 weeks (414) 
 miR-206 Unloading 
Spaceflight 
11 days (415) 





7 days (263) 




1 day (416) 
 miR-499, miR-208b Immobilization 
Hind limb 
suspension 
28 days (263) 





exercise training  
(417) 




8 × 5 unilateral leg press 
repetitions on each leg  
(418) 
 
